1st Canadian Respiratory Conference: A Breath of Fresh Air
June 19 – 21, 2008
Montreal, Quebec


The present supplement is a synopsis of presentations from the founding Canadian Respiratory Conference of June 2008, in Montreal, Quebec. I would like to acknowledge the supplement editors – Drs Kylie Hill and Samir Gupta – who have worked closely in cooperation with the many authors to bring it to you in an abbreviated format. The Journal welcomes your feedback to enable us to plan future conference supplements.

The meeting was a great success, with over 600 attendees. The co-location of so many of our affiliated respiratory clinical, academic, teaching and research societies greatly added to its strength, as did the presence of our colleagues in pediatric respiratory medicine. My thanks to the four founding partners (the Canadian Lung Association, the Canadian Thoracic Society, the Canadian Respiratory Health Professionals and the Canadian COPD Alliance) as well as the conference organizing committee, the scientific program committee and the university division directors across the country, all health care professional participants, the organizing staff and our sponsors, for enabling this conference to achieve its success.

The material included from the plenary and concurrent sessions, as well as the poster session abstracts, reflect the depth and breadth of the meeting. Several of the faculty are internationally recognized for their expertise in respiratory health. The program itself further confirms that Canadian respiratory medicine has reached a critical mass and maturity as a multidisciplinary specialty of which we can be proud. Our next meeting will be held in Toronto on April 23 to 25, 2009, and we look forward to seeing you there.

Roger Goldstein, Chair, Scientific Program Committee

GRADE: An emerging consensus within the respiratory community on rating quality of evidence and strength of recommendations

Gordon H Guyatt MD
Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario
E-mail guyatt@mcmaster.ca

Because guideline developers are inconsistent in how they rate quality of evidence and grade strength of recommendations, guideline users face challenges in understanding the messages that grading systems communicate. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group (1) offers unique advantages over other rating systems (Table 1) (2).

TABLE 1
GRADE advantages
- Developed by a representative group of international guideline developers
- Separation between quality of evidence and strength of recommendations
- Evaluation of the importance of outcomes of alternative management strategies
- Comprehensive criteria for downgrading and upgrading quality of evidence ratings
- Transparent process of moving from evidence to recommendations
- Acknowledgement of values and preferences
- Pragmatic interpretation of ‘strong’ versus ‘weak’ recommendations
- Also useful for systematic reviews and health technology assessments

QUALITY OF EVIDENCE
What is ‘quality of evidence’ and why is it important?
In making health care management decisions, patients and clinicians must trade off the benefits and downsides of alternative
strategies. Decision-makers will be influenced by the best estimates of the expected advantages and disadvantages, as well as their confidence in these estimates.

Recommendations must take account of the quality of evidence (3). For example, organizations recommended that post-menopausal women use hormone replacement therapy (4) believing that it decreased cardiovascular risk. However, these data came from observational studies with inconsistent results (very low quality) (5). Randomized controlled trials (RCTs) have shown that hormone replacement therapy fails to reduce cardiovascular risk, and may even increase it (6,7).

Some antiarrhythmic agents were recommended based on their ability to reduce asymptomatic ventricular arrhythmias associated with sudden death. However, arrhythmia reduction only reflected indirectly on the outcome of sudden death, so the evidence of benefit was of low quality. An RCT demonstrated that the risk of sudden death was increased (8).

Failure to recognize high-quality evidence occurred when recommendations lagged a decade behind good RCT evidence that thrombolytic therapy reduced mortality in myocardial infarction (9). Insufficient attention to quality of evidence risks inappropriate guidelines and recommendations.

How should guideline developers alert clinicians to quality of evidence?
A formal system that categorizes quality of evidence – from high to very low – represents an obvious strategy, but has some limitations. Because quality of evidence is a continuum, any discrete categorization involves some degree of arbitrariness. Nevertheless, the advantages of simplicity, transparency and vividness outweigh these limitations.

Strength of recommendation
A recommendation for treatment may arise from large, rigorous RCTs that demonstrate consistent impressive benefits with few side effects and minimal inconvenience and cost; for example, a short course of oral steroids for asthma exacerbation. Alternatively, recommendations may arise from observational studies that involve harms, burdens or costs. Antithrombotic therapy in pregnant women with prosthetic heart valves must trade off the magnitude of reduction in valve thrombosis, inconvenience, cost and risk of teratogenesis. Clinicians offering such treatments must help patients weigh the desirable and undesirable effects carefully according to their values and preferences.

Guidelines must indicate whether there is high-quality evidence with the desirable effects outweighing the undesirable effects, or whether there is a close or uncertain balance.

GRADING SYSTEMS
Grading systems should separate the quality of evidence from the strength of recommendations. High-quality evidence doesn’t necessarily imply strong recommendations, and strong recommendations can arise from low-quality evidence.

Patients with a first deep venous thrombosis and no obvious provoking factor must decide whether to continue warfarin long term. High-quality RCTs show that continuing warfarin decreases the risk of recurrent thrombosis, at the cost of increased risk of bleeding and inconvenience. Because patient values and preferences will result in different choices, guideline panels should – despite the high quality evidence – offer a weak recommendation.

There is an association between acetylsalicylic acid administration and Reye syndrome (10). Because acetylsalicylic acid and acetaminophen are similar in their analgesic and antipyretic effects, the low-quality evidence regarding the association between acetylsalicylic acid and Reye syndrome does not preclude a strong recommendation for acetaminophen. Explicit criteria for ratings of quality and grading of strength enable judgments to be more transparent (2). GRADE has been widely adopted in the respiratory community where it is used by most major European and North American organizations.

Quality of evidence
GRADE classifies quality of evidence as high, moderate, low and very low (Table 2). RCT evidence is high quality, but five factors may decrease our confidence in the evidence:
• Study limitations
• Inconsistency of results
• Indirectness of evidence
• Imprecision
• Reporting bias

While cohort and case-control studies are ‘low quality’, grading upwards may be warranted if the treatment effect is very large (hip replacement), if there is evidence of a dose-response relationship, or if all biases increase the magnitude of an apparent treatment effect.

TABLE 2

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Further research is very unlikely to change our confidence in the estimate of effect</td>
</tr>
<tr>
<td>Moderate</td>
<td>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate</td>
</tr>
<tr>
<td>Low</td>
<td>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate</td>
</tr>
<tr>
<td>Very low</td>
<td>Any estimate of effect is very uncertain</td>
</tr>
</tbody>
</table>

Strength of recommendation
Recommendations are ‘strong’ or ‘weak’. If an intervention’s desirable effects outweigh its undesirable effects, or clearly do not, the recommendations are strong. If tradeoffs are less certain (low-quality evidence or a balanced desirable and undesirable effects) the recommendations are weak. Table 3 summarizes the factors that affect the strength of recommendations.

TABLE 3

<table>
<thead>
<tr>
<th>Factor</th>
<th>Strong recommendations</th>
<th>Weak recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality of evidence</td>
<td>High-quality randomized trials show the benefit of inhaled steroids in asthma</td>
<td>Only case series have examined the utility of pleurodesis in pneumothorax</td>
</tr>
<tr>
<td>Uncertainty about the balance between desirable and undesirable effects</td>
<td>ASA in myocardial infarction reduces mortality with minimal toxicity, inconvenience and cost</td>
<td>Warfarin in low-risk patients with atrial fibrillation results in small stroke reduction but increased bleeding risk and substantial inconvenience</td>
</tr>
</tbody>
</table>

Continued on next page
TABLE 3 – CONTINUED
Factors that affect the strength of a recommendation

<table>
<thead>
<tr>
<th>Factor</th>
<th>Strong recommendations</th>
<th>Weak recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncertainty or variability in values and preferences</td>
<td>Young patients with lymphoma place a higher value on the life-prolonging effects of chemotherapy over treatment toxicity</td>
<td>Older patients with lymphoma may not place a higher value on chemotherapy over treatment toxicity</td>
</tr>
<tr>
<td>Uncertainty about whether the intervention represents a wise use of resources</td>
<td>The low cost of ASA as prophylaxis against stroke in patients with transient ischemic attacks</td>
<td>The high cost of clopidogrel and dipyridamole/ASA as prophylaxis against stroke in patients with transient ischemic attacks</td>
</tr>
</tbody>
</table>

ASA Acetylsalicylic acid

CONCLUSION
A summary of quality of evidence and strength of recommendations can aid clinicians in using formal guidelines. The GRADE system represents a clear, transparent approach, adopted by leading respiratory organizations.

CONFLICTS OF INTEREST: Dr Guyatt is a member of the GRADE working group, has an intellectual investment in the wide adoption of GRADE, and receives invitations to various events and offers for consultation in part as a function of his involvement with GRADE.

REFERENCES

New developments in the pharmacotherapy of asthma

Louis-Philippe Boulet MD FCCP FRCPC
Centre de pneumologie, Institut de Cardiologie et de pneumologie de l’Université Laval, Hôpital Laval, Québec
E-mail lpboulet@med.ulaval.ca

Reviews of potential new targets and agents for the treatment of asthma have been published in recent years (1-4). This document briefly summarizes some potential new targets for asthma therapy (Table 1).

TABLE 1
Potential new asthma medications*

<table>
<thead>
<tr>
<th>Category</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>Muscarinic receptors antagonists. Theophylline derivatives</td>
</tr>
<tr>
<td></td>
<td>Atrial natriuretic peptide Ultra-long-acting β2-agonists</td>
</tr>
<tr>
<td></td>
<td>Potassium channel openers Vasactive intestinal peptide</td>
</tr>
<tr>
<td></td>
<td>Prostaglandin E2</td>
</tr>
<tr>
<td></td>
<td>Agents acting on airway inflammation and/or remodelling</td>
</tr>
<tr>
<td></td>
<td>Antagonists of endothelin receptors Immunomodulators (T-cells)</td>
</tr>
<tr>
<td></td>
<td>Antagonists of proinflammatory cytokines Kinase inhibitors</td>
</tr>
<tr>
<td></td>
<td>Anti-inflammatory cytokines LT/5-LO/FLAP inhibitors</td>
</tr>
<tr>
<td></td>
<td>Blockers of inflammatory cell migration Nicotine receptors agonists</td>
</tr>
<tr>
<td></td>
<td>Drugs acting on neutrophils Nitric oxide inhibitors</td>
</tr>
<tr>
<td></td>
<td>Fibrogenic cytokine antagonists Phosphodiesterase inhibitors</td>
</tr>
<tr>
<td></td>
<td>Gene therapy Soft/disassociated corticosteroids</td>
</tr>
<tr>
<td></td>
<td>Heparin-like substances Transcription factor inhibitors</td>
</tr>
<tr>
<td></td>
<td>Immunoglobulin E inhibitors Tryptase inhibitors</td>
</tr>
</tbody>
</table>

*Partial list. 5-LO 5-lipoxygenase; Flap 5-lipoxygenase activating protein; LT Leukotriene

POTENTIAL NEW TARGETS FOR ASTHMA THERAPY

New bronchodilators
Ultra-long β2-receptor agonists (24 h) such as indacaterol showed fast and prolonged (greater than 24 h) bronchodilation and are well tolerated (5). A variety of new agents with bronchodilating properties have been studied, but their frequent side effects and/or poor efficacy, especially when compared with the highly effective β2-agonists, make their usefulness uncertain (2,3).

Novel corticosteroids
The nonhalogenated inhaled corticosteroid ciclesonide, activated by lung esterases, has a favourable safety profile with efficacy that is at least equivalent to currently used inhaled corticosteroids (6). The new so-called dissociated corticosteroids, which can selectively transrepress proinflammatory genes without transactivation of genes involved in the metabolic effects of corticosteroids, are currently being investigated.

Phosphodiesterase inhibitors
Phosphodiesterases break down cyclic nucleotides such as cyclic AMP and act on airway smooth muscle as well as on immune and neural mechanisms. Phosphodiesterase-4 inhibitors such as cilomilast and roflumilast have shown some benefit in asthma (2,7).
5-LO/FLAP inhibitors
New agents that could possibly block not only the cysteinyl leukotrienes, but also leukotriene B4, therefore possibly influencing neutrophil as well as eosinophilic inflammation, could be of interest (8).

Immunomodulators acting on T cells, and immunotherapy
A shift in the helper T cells (Th) Th1/Th2 balance may induce a tolerance to allergens and may be useful in the treatment and prevention of allergic diseases. In this regard, immunotherapy with ‘CpG’ DNA oligonucleotides may reduce airway inflammation and hyperresponsiveness in animal models (9). Vaccination with Bacille Calmette-Guérin has been proposed to induce protective effects in increasing Th1 responses, although more studies are needed (10).

Inhibitors of transcription factors
Various transcription factors such as nuclear factor-κB, nuclear factor-κB, and GATA-binding protein 3 are involved in the expression of inflammatory genes and may be a target for inhibitors (11).

Nicotinic receptor agonists
Nicotinic agonists may inhibit various aspects of the inflammatory response and recently developed analogues have provided interesting preliminary results (12).

Antagonists of proinflammatory cytokines
Various agents have been developed to block the effects of interleukins (ILs) such as IL-4, IL-5, IL-9, IL-13 and GM-CSF. In regard to IL-5 antagonists, ‘mepolizumab’ suppressed allergen-induced eosinophilic influx but not clinical asthmatic responses, and did not improve clinical measures of asthma (13). Such agents may be more effective in patients with high levels of eosinophils. Other potential targets include IL-4 and IL-13, two closely related ILs that play a role in immunoglobulin (Ig)E sensitization by B cells, and IL-9, a Th2 cytokine (14). Patients with refractory asthma may also have evidence of upregulation of the tumour necrosis factor-alpha, and etanercept, an IgG1-tumour necrosis factor p75 receptor fusion protein, has been associated with a significant reduction in airway inflammation and hyperresponsiveness and improvement in asthma-related quality of life in severe asthma (15).

Anti-inflammatory cytokines
IL-10 inhibits the synthesis of many inflammatory proteins and may have anti-inflammatory properties that are useful in asthma. Interferon-alpha treatment may possibly reduce corticosteroid requirements in corticosteroid-resistant asthmatic patients (16). Other anti-inflammatory cytokines, including IL-12, IL-18 and interferon-gamma, may be potential targets for therapy.

Agents blocking the migration of inflammatory cells
More than 50 different chemokines act on inflammatory cell recruitment via the activation of G-protein-coupled surface receptors, and may be potential targets for therapy (17). We recently reported that TPI ASM-8, containing two antisense oligonucleotides down-regulating human CC chemokine receptor 3 and the common beta chain of IL-3, IL-5 and granulocyte-macrophage colony-stimulating factor receptors, blunted the increase in total cells after allergen challenge while significantly inhibiting the early asthmatic response (18).

Adhesion molecule inhibitors
Cell adhesion molecules such as selectins and integrins play a major role in cell trafficking and have been under intense investigation as potential new treatments (19). We reported that efalizumab, a monoclonal antibody against the lymphocyte function antigen-1 alpha chain, reduced the allergen-induced late asthmatic response (by 50%) and the postallergen increase in sputum EG2-positive and metachromatic cells (20).

IgE inhibitors
Recombinant humanized monoclonal antibody against IgE (omalizumab) reduces allergen-induced asthmatic responses and has anti-inflammatory effects, while improving asthma and reducing asthma exacerbations, even in patients with relatively severe asthma (21). This mechanism could also be the target of new drugs.

Agents acting on airway remodelling
There is increasing interest in developing drugs that could act on certain aspects of airway remodelling, for example by antagonizing key cytokines such as transforming growth factor-beta, matrix metalloproteinase-9, ADAM-33 and vascular endothelial growth factor (22). This field remains to be explored.

Gene therapy and pharmacotargeting
Genetic markers could help to predict the efficacy and safety of asthma medications in any given individual (23). When the role of specific genes in the development of asthma will be determined, new therapeutic interventions could be developed to influence asthma outcomes.

CONCLUSION
A large number of new targets for asthma therapy have been identified, but it is likely that only a few new agents will demonstrate sufficient efficacy and safety to be of use, particularly in severe asthma. Among those agents, immunomodulators are of particular interest.


REFERENCES

New diagnostics and emerging technologies for tuberculosis

Madhukar Pai MD PhD
Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, & Montreal Chest Institute, Montreal, Quebec
E-mail madhukar.pai@mcgill.ca

Tuberculosis (TB) is a major threat to global health, with nearly nine million people developing TB each year and 1.6 million dying from it (1). TB case detection continues to be a problem, with one-half of all patients being undiagnosed. The situation is worsened by HIV infection, multidrug-resistant TB and extensively drug-resistant TB.

In many settings, TB diagnosis still relies on sputum smear microscopy, culture, tuberculin skin test and chest radiography, tests with known limitations, especially in countries with high HIV rates. Tests for detection of drug resistance are time-consuming, tedious, and inaccessible in many settings.

The involvement of agencies such as the Stop TB Partnership’s Working Group on New Diagnostics, the World Health Organization, the Special Programme for Research & Training in Tropical Diseases, and the Foundation for Innovative New Diagnostics has led to a resurgence of interest in TB diagnostics (2-4). Figure 1 illustrates the types of technology platforms that are currently in the pipeline, from simple microscopic and growth detection systems to molecular and immune-based systems.

![Microscopic visualization of bacteria (e.g. LED microscopy, bleach microscopy)]

![Culture based growth detection tests (e.g. MODS, thin-layer agar, phage-based tests, colormetric media)]

![Nucleic acid amplification tests (e.g. LAMP, Xpert MTB, Transgl DNA detection, Genotype MTBDRPlus)]

![Volatile organic compounds (VOC) detection (e.g. E-Nose, biosensors)]

For latent TB infection, interferon-gamma release assays (5,6) offer in vitro tests, more specific than the tuberculin skin test with several logistical advantages. An improved rESAT-6 based skin test is also under evaluation for latent TB.

For active TB, efforts are being made to optimize sputum smear microscopy using simple light-emitting diode-based fluorescence microscopy systems, and sputum processing methods such as bleach (7,8). Automated liquid cultures (eg, the Mycobacteria Growth Indicator Tube), microscopic observation drug susceptibility, and newer nucleic acid amplification tests such as loop-mediated isothermal amplification are other approaches being evaluated (3,4). While existing serological antibody tests have largely failed (9), antigen detection tests have shown some promise.

For rapid detection of drug resistance, bacteriophage-based tests, microscopic observation drug susceptibility, colormetric culture media and molecular tests such as line probe assays have been evaluated in many settings (10), and line probe assays promise rapid detection of rifampin and isoniazid resistance (10,11).

The TB diagnostics pipeline now includes several technologies showing great promise. With the resurgence of interest in TB control and the recent influx of funding and political support, the...
The challenge of managing multiple drug-resistant tuberculosis

J Mark FitzGerald MD
Respiratory Medicine, University of British Columbia, Vancouver, British Columbia
E-mail markf@interchange.ubc.ca

BACKGROUND

In global terms, tuberculosis (TB) remains a major public health problem (1). Although overall rates of TB are relatively low in Canada, they remain unacceptably high among the foreign-born and marginalized populations including Aboriginal Canadians and the urban poor. In Canada, rates of drug-resistant disease are relatively low, being 11% overall, with 8.6% of cases showing mono resistance, 0.9% multiple drug-resistant TB, (MDRTB – defined as resistance to both isoniazid [INH] and rifampin), and 1.5% of cases showing resistance to more than one drug other than INH or rifampin. Between 1998 and 2007 there were 170 MDRTB cases reported in Canada, with 102 (60%) reported in Ontario and 34 (20%) in British Columbia. This pattern reflects, in part, the fact that both of these provinces receive a disproportionate number of immigrants from high-prevalence TB countries where the number of resistant cases is also higher. So far, there have only been isolated reports of extremely drug-resistant TB (XDRTB) in Canada. XDRTB has recently been redefined as resistance to at least INH, rifampin, any quinolone and at least one of the following injectable drugs: capreomycin, kanamycin or amikacin.

Management of drug-resistant TB

The management of drug-resistant TB involves an initial two-month treatment with at least three drugs: INH, rifampin and pyrazinamide, and where drug resistance is suspected, the addition of ethambutol and/or streptomycin (1). Once drug sensitivities are available, in the presence of a drug-sensitive organism, the continuation phase usually consists of INH and rifampin for a further four months. In the presence of extensive disease and especially if associated with cavitation on chest radiograph and persistent positive cultures at two months, treatment for nine months is recommended (1). The use of directly observed therapy has been recommended in all cases of TB. Although the level of evidence supporting this recommendation has been questioned (2), many still advocate such a treatment modality, especially in the presence of a poor social support network and drug-resistant disease.

TABLE 1 Important principles in the management of drug-resistant tuberculosis

<table>
<thead>
<tr>
<th>Principle</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Start with a standard four-drug regimen</td>
</tr>
<tr>
<td>2.</td>
<td>If resistance is strongly suspected, and especially if the patient has been previously treated, add at least two new drugs not used previously</td>
</tr>
<tr>
<td>3.</td>
<td>Single drugs should never be added to a failing regimen</td>
</tr>
<tr>
<td>4.</td>
<td>Use directly observed therapy</td>
</tr>
<tr>
<td>5.</td>
<td>Perform drug susceptibility on all initial isolates, and subsequently if the regimen is failing</td>
</tr>
<tr>
<td>6.</td>
<td>If resistance is confirmed, use at least three drugs and preferably more known to be active against the organism</td>
</tr>
<tr>
<td>7.</td>
<td>In resistant cases, therapy may be required for 24 months, but at least six months postbacterial conversion</td>
</tr>
<tr>
<td>8.</td>
<td>Drug susceptibility testing should be repeated if cultures remain positive after three months of therapy</td>
</tr>
<tr>
<td>9.</td>
<td>Consider drug level assessments as part of management</td>
</tr>
<tr>
<td>10.</td>
<td>Refer selected cases for surgery</td>
</tr>
</tbody>
</table>

As noted, in the presence of a prior history of treatment for TB, the possibility of drug-resistant TB should be considered. This is especially important if the patient was treated in a region where drug resistance is known to be common. In such cases, an attempt should be made to identify what treatment
the patient received. Although a patient may not be familiar with his or her treatment regimen, it may be documented in immigration papers, especially if a postlanding surveillance was conducted. If the patient does not recall receiving injections as part of his or her TB treatment, it can be assumed that streptomycin was not administered, and this drug may be used, along with a quinolone, most commonly moxifloxacin, in addition to the other first line drugs (INH, rifampin, pyrazinamide and ethambutol). These drugs should be continued until drug sensitivities are available, at which point the treatment regimen can be adjusted accordingly. In the presence of drug-resistant disease, the regimen must be of longer duration, and careful patient follow-up including monitoring not only of clinical but also of bacteriological and radiological response is required.

If the disease is localized, adjunctive therapy with surgical resection has been shown to increase cure rates. Such an intervention needs to be planned carefully, with attention to infection control and involvement of a centre with appropriate surgical expertise. It has been our clinical experience that assessment of drug levels can be especially helpful when a recurrence occurs despite what appears to have been an adequate regimen delivered in a directly observed fashion.

Due to the complexity of regimens needed to treat drug resistant disease, their detailed description is beyond the scope of this brief overview. However, it suffices to say that because of the empirical nature of many of the suggested regimens and their associated toxicity, careful ongoing monitoring for response to therapy and side effects is required. A detailed overview of the management of drug-resistant TB is provided in two recently published papers (4,5).

Unfortunately, XDRTB, especially when it occurs in association with HIV infection, has a dismal prognosis (6). A more recent study from Peru has reported better outcomes (7). A major challenge faced by clinicians caring for such patients is that drug-resistant disease is often not immediately identifiable, and many patients will have died before results from drug sensitivity testing using traditional methods become available. Although there are promising new technologies that will provide drug sensitivities earlier, their availability where they are most needed will be limited for the foreseeable future (8).

In conclusion, although we had effective drug treatment for TB for many years, the convergence of high rates of dual HIV and TB infection coupled with a lack of political will to tackle this issue has now left us with rising rates of TB and the emergence of drug-resistant disease. Overcoming the challenge of drug-resistant TB will be difficult unless there is a fundamental recognition of the global public health impact of these resistant cases. It will also require the discovery of novel new therapies, ideally requiring a shorter duration of treatment, coupled with the widespread availability of better diagnostic technologies, and especially those with the capacity for earlier detection of drug-resistant TB. Unfortunately, the lack of political will to provide the necessary resources to address this issue does not bode well for success (9,10).

ACKNOWLEDGEMENTS: Dr FitzGerald is a recipient of a CIHR/BC Lung Scientist Award and also a Michael Smith Foundation for Health Research Distinguished Scholar Award.

CONFLICTS OF INTEREST: None.

REFERENCES

Keeping ventilated and ‘at-risk’ patients out of the intensive care unit

Douglas A McKim MD
Medical Director, Respiratory Rehabilitation Services, The Ottawa Hospital Rehabilitation Centre, Ottawa, Ontario
E-mail dmckim@ottawahospital.on.ca

PREVENTION

The approximately 70 intensive care unit (ICU) beds in Ontario used by long-term ventilated patients have been estimated to prevent the admission of 1000 to 2000 critical care patients (1). Preventive strategies will reduce critical care utilization in conditions such as neuromuscular diseases (NMD) including amyotrophic lateral sclerosis, spinal cord injury, muscular dystrophies and chest-wall disorders. Patients benefit from preventive techniques of airway management, elective noninvasive ventilation, and most importantly, airway clearance.

Respiratory muscle weakness impairs the ability to ventilate and the ability to cough to clear airway secretions. In NMD, respiratory muscle weakness results in an inadequate vital capacity and insufficient expiratory force to achieve effective cough and airway clearance. Cough capacity declines further during an upper respiratory infection (2). This increases the risk of pneumonia and respiratory failure from a simple upper respiratory tract infection. Once ventilated in an emergency department or an ICU, the risk for long-term invasive ventilation is very high. Bulbar weakness further increases the risk due to an inability to protect the airway and to coordinate glottic function for cough. Peak cough flows (PCF) greater than 160 L/min are necessary to prevent reintubation in patients with NMD (3) and those capable of PCFs 270 L/min or greater are at minimal risk for acute respiratory compromise (4,5).

Lung volume recruitment

Patients with motivation, bulbar function, and sufficient respiratory system compliance can learn to recruit lung volume by adding pressure and volume to the restricted respiratory system. This is termed lung volume recruitment (LVR) or ‘breath-stacking’. It augments expiratory flow rate during coughing. A higher PCF is more effective for airway clearance. LVR is performed by adding sequential volumes of air on top of each other using the glottis as a valve (Figure 1).
LVR is achieved with a modified hand-held resuscitation bag with corrugated tubing, a one-way valve, and a mouth piece or full face mask if significant bulbar impairment is present. Detailed instructions are available at <www.irrd.ca/education> (7).

LVR can also be achieved with a home volume ventilator with a mouth piece, or with glosso-pharyngeal breathing. It is very important to provide visual feedback to patients and to illustrate the numeric value of the unassisted vital capacity and the increase to maximum insufflation capacity (Figure 2). PCFs can be measured using a peak flow meter and expressed in litres per minute, as in asthma. Patients must understand the effect of LVR on PCFs in order to use these techniques during an acute URTI or following aspiration. This circuit must not be applied to a cuffed tracheostomy during resuscitation, because a closed system could result in a tension pneumothorax.

Manually assisted cough

During a cough, compression of the abdomen, just before glottic opening, is referred to as manually assisted cough, sufficient in some individuals to achieve an adequate cough without breath stacking. However, LVR alone is superior to manually assisted cough alone in increasing the maximum insufflation capacity and PCF (8). Augmentation of PCFs allows for adequate airway clearance during an upper respiratory tract infection or following aspiration and has been shown to reduce hospitalization (4).

**Mechanical insufflation-exsufflation, (CoughAssist™)**

The CoughAssist device (http://www.irrd.ca/education) is a bedside apparatus, applied noninvasively through a full face mask, which generates a positive inspiratory pressure to provide lung inflation followed rapidly by a negative pressure to create high expiratory flows that shear mucus away from the airway. It can also be applied through an artificial airway. Although limited by the quality of evidence, reports demonstrate positive outcomes with an absence of adverse effects. The device is most applicable in NMD or chest wall diseases (9).

**Elective noninvasive ventilation**

Patients at risk of respiratory failure should be monitored to determine an appropriate time for initiation of noninvasive ventilation. This varies with the type of NMD, but in general, is applied at the earliest onset of symptoms of sleep-related breathing difficulties, nocturnal desaturation, orthopnea or daytime elevation of CO2 above 45 mmHg. Outpatient initiation has been better accepted by patients and families and achieved similar results to inpatient initiation (10).

**CONCLUSION**

The combination of education and skills in airway clearance techniques and the provision of elective noninvasive ventilation will reduce unnecessary critical care utilization and improve access to critical care beds.

**CONFLICTS OF INTEREST:** None.

**REFERENCES**

Liberation from long-term intensive care unit ventilation

Ian M Fraser MD
Respirology, Toronto East General Hospital and Department of Medicine, University of Toronto, Ontario
E-mail ifras@tegh.on.ca

Prolonged mechanical ventilation, defined as being ventilated for 6 h or more per day for 21 or more days, identifies a patient group at risk for long-term (formerly chronic) ventilation (1). Despite a 50% to 60% weaning rate, one-year survival varies from 23% to 76% in this population, and only 8% to 10% achieve functional independence (1-3). A 2005 survey conducted in Ontario (4) identified acute lung injury/acute respiratory distress syndrome, chronic obstructive pulmonary disease, and nonobstructive lung disease as the major long-term intensive care unit (ICU) ventilation diagnoses.

Mechanisms of ventilator dependence include systemic factors such as comorbid conditions and poor nutrition; mechanical factors such as reduced respiratory muscle capacity due to myopathy/neuropathy, and upper airway obstruction; iatrogenic factors such as inappropriate ventilator settings; medical errors; psychological factors such as delirium, depression, anxiety, and sleep deprivation; and process of care factors such as a lack of weaning and sedation protocols, and inadequate nursing staffing (1).

Weaning venues include the ICU, in-house weaning units, “Tele”-weaning, regional weaning centres and long-term assisted ventilation centres. The ideal patient-focused venue should incorporate: relative quiet and day/night cycles; easily visible outdoors; relative roominess; encouragement of supportive visitors; increased mobility; personal objects; independence; time and devices to increase communication; transition to oral feeding; time, space and personnel for reconditioning; active patient interactions; emphasis on staff nurturing; time and opportunity for counselling; time and space for patient/family palliative care; and home-geared discharge planning (1).

Management can be approached from a health care system, unit and individual patient viewpoint. Health care system management involves strategic planning to avoid unnecessary future ICU use and identification of service and capacity gaps (4). Unit management involves integrating, within local resource availability (5), evidence-based practice, knowledge translation (6) and an understanding of the biases in guideline development (7). “Hardwiring” best practice includes: specific weaning approach (1) (slow-paced with gradually lengthening of self-breathing trials with nonfatiguing comfortable ventilatory support between weaning trials); continuing ICU weaning best practice (daily spontaneous breathing trials, minimized sedation, nurse and/or respiratory therapist weaning protocols, daily wakeup and breathe) (8-10); and minimizing complications (central line and ventilator bundles, daily goals rounds, nutritional support, guideline-directed ventilator-acquired pneumonia treatment) (11-14), and possibly earlier tracheostomy. Optimal individual patient management requires an interdisciplinary team care (15,16), an understanding of ethical issues in long term ventilation, and reliable palliative (17) and follow-up care (18).

In Canada, there are significant observational (prevalence, distribution, outcomes, capacity) and comparative (systematic health care delivery, models of care and outcomes, hardwired unit performance) knowledge gaps as well as a need to develop a national community of practice.

The challenge of liberating these patients in whole or in part from ventilator assistance requires a purposeful strategy by a dedicated interdisciplinary team, evidence-based practice, ethical decision-making and an integrated local approach to health care system delivery.

CONFICT OF INTEREST: None.

REFERENCES
Repatriation, or the road to home ventilation
Jeremy Road MD
Medical Director, Provincial Respiratory Outreach Program, Respiratory Division, Vancouver Coastal Health and the University of British Columbia, Vancouver, British Columbia
E-mail jeremy.road@vch.ca

There is an emerging body of evidence supporting long-term ventilation (LTV) for patients with neuromuscular disease and chronic thoracic restrictive disorders. Moderate-sized, randomized, controlled trials and retrospective studies have shown improvement in quality of life and survival such that the available evidence supports a strong positive recommendation for home ventilation. The data supporting chronic home ventilation in chronic obstructive pulmonary disease are less robust.

LTV can be initiated in the home (home ventilation [HV]), thus avoiding the problem of repatriation. Small studies comparing ventilation initiated at home versus in-hospital have shown similar outcomes (1, 2). However, respiratory failure may precipitate hospitalization and a subsequent need for discharge home (repatriation). The approach to this is discussed below.

The first step is to establish whether the patient has a diagnosis known to benefit from LTV and whether the patient can be safely managed at home. If support is available, patients usually prefer to be at home. However, should they reside far from a support network or have a condition that requires frequent attention, a hospice or ‘low-tech’ hospital may be an alternative to the home.

To be discharged, the patient must be stable, on minimal positive end-expiratory pressure and have modest requirements for supplemental oxygen. Bronchial secretions must also be manageable. Discharge planning is undertaken by a hospital-based case manager who co-ordinates with the home care team. In British Columbia, community respiratory therapists, designated for this purpose, as part of the Provincial Respiratory Outreach Program (PROP), need to be involved early on to establish the home support network before discharge. Caregivers and care aids may need to be trained. Family and friends can act as caregivers, and aids can also be hired, to provide support. If the case manager can address home care provider needs and respiratory therapy needs, repatriation should proceed without difficulty (3).

Potential risks in HV include power failure, ventilator malfunction, accidental disconnection, circuit obstruction, difficulties with the tracheotomy and concurrent medical problems (4). The goal of HV is to minimize risk through client and caregiver education. Tele-Medicine is an evolving technology for following patients in the community (5). The European Ventilation study (6) found that ventilation centre size varied across countries. In Canada, McKim et al surveyed 12 centers and found that 45% of patients on LTV had their ventilation initiated at home (personal communication). The greatest barriers to repatriation were an inadequate caregiver network and nursing issues, both of which often relate to resource insufficiency.

The BC Association of Individualized Technology and Supports for People with Disabilities enables people to meet their respiratory and assisted devices needs within a community-based environment that is responsive to and respectful of their individual goals. The organization includes: Technologies for Independent Living, which produces electronic devices for living at home, and the PROP, which provides comprehensive services for individuals needing assisted ventilation. PROP services include a ventilator pool and all respiratory supplies. Education and communication is a cornerstone of the PROP program, using written and Web-based materials, client booklets, manuals and client as well as caregiver training. The program has grown from 279 patients in 2002 to 395 in 2007. Ventilators are purchased through a selection committee of clients, a respirologist, respiratory therapists and biomedical engineers, trained to service and maintain equipment, at no charge to the client.

After identifying an HV patient, the case manager contacts the PROP and begins the process of educating the caregivers. Advantages of the PROP program include accessibility, standardization of quality of care, an equipment pool with trained engineers, and a database. This program is cost-saving, while satisfying caregivers and improving patient quality of life.

CONFLICTS OF INTEREST: Nothing to declare in regard to the content of the present article.

ACKNOWLEDGEMENTS: The author would like to recognize the hard work and commitment to patient care of the PROP team.

REFERENCES

Assessing activity limitation in chronic obstructive pulmonary disease
Darcy D Marciniuk MD FRCPC
Division of Respirology, Critical Care and Sleep Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan
E-mail darcy.marciniuk@usask.ca

Activity limitation is a cardinal symptom of chronic obstructive pulmonary disease (COPD). In optimizing management of these patients, the clinician must therefore be aware of the differing methods of evaluating activity limitation and exercise responses, the evidence supporting their utility, and be able to select and perform the most appropriate test.

Assessing activity limitation in COPD enables objective evaluation of the integration of respiratory, cardiovascular and metabolic function. Exercise places an increased demand on the
functional reserve of the body, and because organs (and in particular, the lungs) have such a large physiological reserve, impairment may not become apparent at rest until functional capacity is significantly reduced. Both exercise performance and aerobic capacity correlate with mortality in COPD (1,2). Recognizing the importance of both symptoms and disability, the recent “Canadian Thoracic Society recommendations for management of Chronic Obstructive Pulmonary Disease – 2007 update” (3) proposed a disease stratification based on either symptoms and disability (as assessed by the Medical Research Council dyspnea scale), or impaired lung function (as assessed by spirometry).

There are many options for assessing activity limitation in COPD (Table 1), beginning with a thorough clinical assessment, which is often all that is required. When more objective evaluation is desired, simple tests are readily performed and more widely available, but provide limited physiological understanding, while comprehensive tests are more technically demanding and less widely available, but provide further information and understanding.

**TABLE 1**

Options for assessing activity limitation and exercise performance in chronic obstructive pulmonary disease

- Clinical history and assessment
- Questionnaires (self-reported physical activity)
- Activity motion sensors – pedometers, accelerometers
- Stair climbing
- Timed walk tests – 6 min or 12 min walk test
- Shuttle walk test – incremental or endurance protocols
- Cardiopulmonary exercise testing – incremental or endurance protocols

Questionnaires are a simple and validated technique, but are subject to the limitations of any self-reported data. Similarly, stair-climbing testing has become less popular with the advent of other validated techniques that yield more meaningful and reproducible data.

The popularity of activity motion sensors is increasing. Pedometers are simple and economical, and their use has been validated in other populations (5,6). Although more costly, accelerometers provide additional information and are more sensitive than pedometers for light-intensity activities (characteristic of COPD) such as slow walking. Reports using accelerometers have recently shown that pulmonary rehabilitation programming lasting longer than three months may be necessary to significantly enhance daily physical activity in COPD patients (7).

Timed walk tests (typically 6 min or 12 min) are the standard ‘simple’ test for assessing activity limitation. They are safe and practical, and mimic activities of daily living. Their utility has been shown to improve with standardization, although they are susceptible to a training effect (similar to other tests). Though they provide restricted information regarding physiologic contributors and mechanisms of exercise limitation, they are now used commonly (8).

Shuttle walk tests are another emerging option, and recent reports have validated their usefulness in detecting a treatment effect in this population (9,10). As further reports validating their utility are published, our understanding of the role of both incremental and endurance protocols will mature.

Finally, cardiopulmonary exercise testing is the gold standard for assessing exercise performance. It provides for mechanistic insights, recognition of coexistent and multiple exercise-limiting factors, and a thorough evaluation of respiratory responses and constraint. Both incremental and endurance protocols may be used, and endurance protocols have been found to be more responsive to treatment than either incremental exercise or 6 min walk tests. Though testing is not widely available, if a thorough evaluation of exercise performance is required, particularly in patients with multiple comorbidities, it remains the test of choice.

**CONFLICTS OF INTEREST:** None.

**REFERENCES**


**Optimizing exercise: Practical strategies to improve exercise rehabilitation**

Neil D Eves PhD1,2, Warren J Davidson MD2, Gordon T Ford MD*

1Faculty of Kinesiology, 2Division of Respiratory Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta

*E-mail neves@ucalgary.ca

Respiratory rehabilitation improves exercise capacity, health-related quality of life (HRQL) and exertional symptoms in patients with chronic obstructive pulmonary disease (COPD) (1), and may help reduce health care utilization (2) and mortality (3). The essential component of rehabilitation is exercise, as it has the potential to alter the underlying physiology of the disease (4,5). While exercise of any form is beneficial to sedentary patients, it is more difficult to maximize the benefits of exercise for each patient throughout rehabilitation and an individualized, well-structured exercise program is often needed to optimize outcomes (6).
While exercise programs designed for athletes are often too complex for patients with COPD, appreciating the principles on which they are based can make exercise prescriptions more effective. Figure 1 depicts a number of training principles that should be considered when attempting to optimize rehabilitation for patients with COPD. Examples include: 1) individuality principle – because patients with COPD have different limitations to exercise, differing abilities to perform functional tasks, and a wide variety of comorbidities, exercise should be tailored to the needs of each individual; 2) specificity principle – exercises should be prescribed to specifically improve identified functional deficits; 3) progressive overload principle – workloads greater than habitual levels should be prescribed and progressed over time to ensure continued improvement; 4) variety principle – the mode and types of exercise should be varied to ensure that exercise continues to be enjoyed and beneficial and behaviours are maintained following rehabilitation; and 5) regularity and rest and recovery principles – patients should be encouraged to exercise regularly in addition to rehabilitation but with adequate rest to promote optimal physiological adaptation while avoiding excessive fatigue.

Individual responses to any rehabilitation program vary, and some patients may be unable to achieve the necessary volume (intensity × duration × frequency) of exercise to gain noticeable improvements in functional status. This is especially true for those with debilitating dyspnea and it may be necessary to use alternative or adjunct strategies to increase the intensity and/or duration of exercise. Of the growing number of strategies available, interval training and oxygen supplementation are likely the most practical. Interval training consists of multiple bouts of high intensity exercise interspersed with periods of recovery, which allows patients to perform at higher exercise intensities with similar, or reduced, dyspnea (7). In addition to the known benefits of oxygen for maintaining arterial saturation, oxygen supplementation may also be beneficial for nonhypoxemic patients as oxygen slows ventilation and reduces dyspnea (8). As a result, oxygen supplementation allows patients to perform a greater intensity of exercise and gain greater benefits from exercise training (9). Another more novel strategy may be the use of helium-hyperoxia, which reduces dyspnea more than oxygen or normoxic-helium (10). Breathing helium-hyperoxia during exercise rehabilitation increases the intensity and duration of exercise that patients with COPD can perform and results in greater improvements in exercise tolerance and health-related quality of life compared with the standard practice of rehabilitation (11).

In summary, the benefits of respiratory rehabilitation in patients with COPD are well known, and a number of practical changes in exercise prescription may further augment these benefits. Furthermore, using novel strategies to reduce exertional symptoms may also enable patients to perform a greater volume of exercise and optimize the benefits of a rehabilitation program.

CONFLICTS OF INTEREST: None.

REFERENCES

Management and prevention of venous thromboembolism: The 8th American College of Chest Physicians Guidelines
William Geerts MD FRCP
Thromboembolism Program, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario
E-mail William.Geerts@Sunnybrook.ca

THE IMPORTANCE OF VENOUS THROMBOEMBOLISM
Venous thromboembolism (VTE) is a common disease with two linked components, deep vein thrombosis (DVT) and pulmonary embolism (PE). Symptomatic VTE occurs in more than one of every 1000 persons in the population every year. It is associated with increased mortality and with substantial acute and long-term morbidity.

THE AMERICAN COLLEGE OF CHEST PHYSICIANS ANTITHROMBOTIC GUIDELINES
The American College of Chest Physicians (ACCP) Guidelines (1-3) are prepared by multidisciplinary, international groups of
can Respir J vol 15 Suppl C November/December 2008

The guidelines on the treatment of VTE (2) emphasize that, with few exceptions, the acute and long-term management of patients with DVT or with PE is identical. For most patients with VTE, anticoagulation with fixed-dose low molecular weight heparin (LMWH) based on body weight is the initial treatment of choice; no dosage adjustment or laboratory monitoring are subsequently required unless the patient has at least moderate renal dysfunction. For both DVT and nonmassive PE, subcutaneous LMWH is recommended over intravenous heparin. In addition to subcutaneous LMWH and intravenous heparin, two new, but infrequently used, acute treatment options have been added: fixed subcutaneous doses of the factor Xa inhibitor, fondaparinux, and unfractionated heparin given subcutaneously in doses that are based on body weight without the need for either dose alteration or laboratory monitoring. Most patients with DVT and many patients with hemodynamically stable PE can be treated as outpatients. Early ambulation is recommended for both DVT and PE.

The new guidelines recommend rapid risk stratification to identify patients with acute PE who have hemodynamic compromise to determine if thrombolytic therapy or catheter-directed interventions should be considered. If appropriate expertise is available, catheter-directed pharmaco-mechanical thrombus reduction is also suggested for selected patients with acute iliofemoral DVT. The guidelines recommend against the insertion of an inferior vena cava filter unless the patient has acute VTE and a contraindication to therapeutic anticoagulation. In these situations, removable filters are preferred and conventional anticoagulation should be implemented when the high bleeding risk resolves.

For most patients with acute VTE, warfarin should be started on the same day as LMWH, heparin or fondaparinux, and should overlap with the parenteral anticoagulant for at least five days and until the patient’s international normalized ratio is at least 2.0 for 24 h. For VTE in cancer patients, the guidelines recommend that LMWH, heparin or fondaparinux is given subcutaneously in doses that are based on body weight without the need for either dose alteration or laboratory monitoring. Most patients with DVT and many patients with hemodynamically stable PE can be treated as outpatients. Early ambulation is recommended for both DVT and PE.

The new guidelines recommend rapid risk stratification to identify patients with acute PE who have hemodynamic compromise to determine if thrombolytic therapy or catheter-directed interventions should be considered. If appropriate expertise is available, catheter-directed pharmaco-mechanical thrombus reduction is also suggested for selected patients with acute iliofemoral DVT. The guidelines recommend against the insertion of an inferior vena cava filter unless the patient has acute VTE and a contraindication to therapeutic anticoagulation. In these situations, removable filters are preferred and conventional anticoagulation should be implemented when the high bleeding risk resolves.

For most patients with acute VTE, warfarin should be started on the same day as LMWH, heparin or fondaparinux, and should overlap with the parenteral anticoagulant for at least five days and until the patient’s international normalized ratio is at least 2.0 for 24 h. For VTE in cancer patients, the guidelines recommend therapy with LMWH rather than warfarin at least for the first three months of treatment and perhaps longer.

The guidelines clarify the duration of anticoagulation after VTE. For DVT or PE associated with a reversible cause, three months of anticoagulation with warfarin (international normalized ratio 2.0 to 3.0) is recommended. For VTE that is unprovoked, indefinite anticoagulation is recommended if the risks of anticoagulation are acceptable and if the patient agrees.

In cases where long-term anticoagulation is instituted, periodic reassessment of this decision should be performed.

Prevention of venous thromboembolism

Approximately 70% of all VTE is related to hospitalization. Because VTE is one of the most common complications of hospital stay and is associated with substantial short- and long-term morbidity and death, prevention is the key to reducing the burden of this disease (3). Several hundred clinical trials confirm the effectiveness, safety and cost-effectiveness of thromboprophylaxis for a variety of patient groups. The use of recommended thromboprophylaxis has been shown to reduce the risk of DVT, proximal DVT, PE and fatal PE by more than 60%.

The guidelines discuss the risks of VTE separately in 23 patient groups and the evidence for thromboprophylaxis (or not) in each of these groups with particular emphasis on randomized clinical trials. It is recommended that every general hospital develop a formal, active strategy to prevent VTE, which should generally be in the form of a written, institution-wide thromboprophylaxis policy. Mechanical thromboprophylaxis with compression stockings, pneumatic compression devices or foot pumps is recommended for patients at high risk of bleeding. Particular attention should be directed toward ensuring the proper use of, and optimal adherence with, mechanical methods of prophylaxis. Furthermore, it is recommended that pharmacologic prophylaxis be substituted for or added to the mechanical prophylaxis when the high bleeding risk decreases. The guidelines recommend against the use of acetylsalicylic acid alone as venous thromboprophylaxis for any patient group.

A summary of the 2008 ACCP Guidelines on the Prevention of VTE is found in Table 1. Most hospital patients at risk for VTE should continue thromboprophylaxis until discharge and not stop as soon as they start to ambulate. For major orthopedic surgery, the recommended duration of prophylaxis is at least 10 days with a strong recommendation to continue for up to five weeks.

| TABLE 1 |

<table>
<thead>
<tr>
<th>Risk groups and recommended thromboprophylaxis options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk group</strong></td>
</tr>
<tr>
<td>Low TE risk</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Moderate TE risk</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>High TE risk</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>High bleeding risk</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*For further details, see the 8th ACCP Conference on Antithrombotic Therapy (3). GCS Graduated compression stockings; INR International normalized ratio; PCD Pneumatic compression device; TE Thromboembolism; VFP Venous foot pump |

**CONFLICTS OF INTEREST:** Dr Geerts has received research support, honoraria or fees as a consultant for: Bayer Healthcare, Boehringer-Ingelheim, Coviden, Daiichi Sankyo, Leo Pharma, Pfizer and Sanofi Aventis.
Advances In endoscopic imaging

Stephen Lam MD FRCP, Annette McWilliams MB FRCP, Michael Short PhD, Calum MacAulay PhD, Haishan Zeng PhD Cancer Imaging Department, BC Cancer Agency & the University of British Columbia, Vancouver, British Columbia E-mail slam2@bccancer.bc.ca

INTRODUCTION

Imaging modalities such as computed tomography, magnetic resonance imaging and ultrasound can detect objects in the sub-millimetre scale (Table 1). Optical imaging such as autofluorescence bronchoscopy, optical coherence tomography (OCT) or confocal microendoscopy offer resolution down to the submicron range, measuring biochemical, structural and functional changes in cells and tissues (Table 2).

TABLE 1

Resolution of thoracic imaging modalities

<table>
<thead>
<tr>
<th>Multidetector CT scanner</th>
<th>MRI</th>
<th>Ultrasound</th>
<th>OCT</th>
<th>Confocal microendoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.6 mm</td>
<td>~300 µm</td>
<td>~50 µm</td>
<td>2 µm-6 µm</td>
<td>0.3 µm</td>
</tr>
</tbody>
</table>

CT: Computed tomography; MRI: Magnetic resonance imaging; OCT: Optical coherence tomography

TABLE 2

Optical imaging in bronchoscopic assessment

<table>
<thead>
<tr>
<th>Structural features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surface: Broad-band (white) light reflectance imaging</td>
</tr>
<tr>
<td>Depth: Optical coherent tomography; confocal microscopy</td>
</tr>
<tr>
<td>Microvasculature: Narrow band imaging</td>
</tr>
<tr>
<td>Molecular/biochemical/functional changes</td>
</tr>
<tr>
<td>Fluorescence imaging</td>
</tr>
<tr>
<td>Confocal microscopy</td>
</tr>
<tr>
<td>Optical coherence tomography + multiphoton microscopy</td>
</tr>
<tr>
<td>Raman spectroscopy</td>
</tr>
</tbody>
</table>

White-light bronchoscopy

White-light bronchoscopy (WLB) is the simplest and most commonly used endoscopic imaging method. It makes use of differences in the specular reflection, back scattering and absorption properties of white light to define the structural features of the bronchial surface to discriminate between normal and abnormal tissues. Although useful when there are alterations in surface features (eg, invasive lung cancer), it is insensitive to subtle changes (eg, preinvasive lung cancer) at or below the epithelial surface.

Narrow band imaging

Narrow band imaging uses blue light (at 415 nm) and green light (at 540 nm) corresponding to the maximal hemoglobin absorption peaks. Blue light highlights superficial capillaries and green light penetrates deeper to highlight larger blood vessels in the submucosa. Narrow band imaging improves detection of dysplasia and carcinoma in situ compared with WLB (1).

Autofluorescence bronchoscopy

Autofluorescence bronchoscopy uses fluorescence to provide information about the biochemical composition and metabolic state of bronchial tissues. The most important fluorophores are structural proteins such as collagen and elastin, and those involved in cellular metabolism such as NADH and flavins. The fluorophores determine the fluorescence properties of bronchial tissue (2). As the bronchial epithelium changes from normal through to dysplastic, carcinoma in situ and invasive cancer, there is a progressive decrease in green autofluorescence with less decrease in red fluorescence intensity (2).

The spectral differences between 500 nm and 700 nm in normal, premalignant and malignant tissues are the basis for autofluorescence endoscopic imaging devices for localization of early lung cancer in the bronchial tree. In addition to multiple single-center studies, there are three multicentre clinical trials and two randomized trials that showed improved detection rate with autofluorescence bronchoscopy or fluorescence-reflectance bronchoscopy compared with WLB alone (3).

Confocal microendoscopy

There are two imaging modalities that have sufficient spatial resolution and tissue depth penetration to study the bronchial epithelial and subepithelial changes associated with airway diseases. Confocal microendoscopy offers spatial resolution at the submicron range, but although the basement membrane and upper submucosa can be imaged with superb quality, the epithelial cells are not visible without contrast agents (4). The development of molecularly targeted contrast agents enables disease-specific morphological and biochemical processes to be labelled with unique optical signatures. For example, epidermal growth factor receptor expression in cells can be imaged in-vivo using epidermal growth factor receptor-gold nanoparticle conjugates and confocal microscopy to study the carcinogenesis process (5).

OCT

OCT is a noncontact imaging method that allows rapid scanning of a larger surface area. Near infrared light allows imaging of cellular and extra-cellular structures with a spatial resolution of 2 µm to 16 µm and a depth penetration of approximately 2 mm, to image through the bronchial wall for visualization of carcinoma in situ, high-grade dysplasia or invasion through the basement membrane (6). Fibre optic probes can be miniaturized to enable imaging of airways down to the terminal bronchiole beyond the range of a standard bronchoscope. Preliminary study suggests that OCT is a more sensitive tool in detecting airway wall remodelling in smokers compared with computed tomography scans, and raises the possibility that OCT could be used to study airway changes in vivo in patients with chronic obstructive pulmonary disease to assess the therapeutic potential of novel airway therapies (7).
Spectroscopy
Spectroscopic measurements during bronchoscopy provides information regarding the physiological state and chemical composition of bronchial tissues (8). Oxygen saturation and blood volume can be measured using reflectance spectroscopy (9), and Raman spectroscopy provides information on the molecular composition and structure of a material, through inelastic scattering of light, first described in 1928 by Raman and Kirishnana (10); Raman subsequently received a Nobel prize for this work. When light strikes a molecule, most of it is scattered at the same frequency as the incident light but a small fraction is scattered at a different wavelength. The frequency difference between incident and Raman scattered light is termed the Raman shift, and can provide a molecular signature of the material. Studies in excised bronchial and lung tissue (11) as well as in vivo study (12) suggest Raman spectroscopy may differentiate premalignant from malignant lesions and from normal tissue.

SUMMARY
Recent advances in optical imaging provide unprecedented opportunities to study the biology and mechanisms of airway diseases in vivo, improve clinical diagnosis, and offer the potential to monitor the effect of therapeutic interventions.

CONFLICTS OF INTEREST: None.

REFERENCES

Endobronchial ultrasonography:
Bronchoscopy beyond the airway wall
Alain Tremblay MDCM FRCPC FCCP
Division of Respiratory Medicine, Department of Medicine,
University of Calgary, Calgary, Alberta
Email alain.tremblay@ucalgary.ca

INTRODUCTION
Endobronchial ultrasonography (EBUS) is rapidly changing the approach to the diagnosis of lung disease. The balloon sheath and peripheral EBUS consists of a small 1.2 mm to 1.7 mm, 20 MHz radial ultrasound (US) probe inserted through the working channel of a standard flexible bronchoscope (Figure 1A), resulting in a radial field of view (Figure 1B), while the linear EBUS consists of a dedicated bronchoscope with a 7.5 MHz US probe integrated into the tip of instrument (Figure 2A).

Figure 1) Peripheral endobronchial ultrasonography. A Radial ultrasound probe (1.7 mm diameter) and guide sheath inserted through the working channel of a standard bronchoscope. B Ultrasound image of a peripheral lung nodule

BALLOON SHEATH EBUS
A radial probe is placed in a balloon-tipped sheath filled with saline for an air-free interface between the probe and the airway. High resolution images of the central airway allow for staging lung, esophageal and thyroid malignancies (1), as well as managing carcinoid tumours, early lung cancers or carcinoma in situ. For locating mediastinal lymph nodes before transbronchial needle aspiration (TBNA) (2), this approach has been supplanted by linear EBUS.
PERIPHERAL EBUS

The radial probe inserted through a guide-sheath or ‘extended working channel’ is used to locate peripheral lung lesions beyond the usual view of the bronchoscope (Figures 1A and 1B). The probe is then removed, leaving the guide sheath through which biopsy forces, brushes or needles are advanced for sampling. Diagnostic yields are 60% to 80% and randomized trials have confirmed increased yields compared with standard transbronchial biopsy (3). EBUS can also be used in combination with electromagnetic guidance navigational bronchoscopy (4). The US image may suggest whether lesions are benign or malignant (5).

LINEAR EBUS

This technique allows real-time visualization and needle aspiration of mediastinal and proximal lung lesions with a dedicated 22 gauge needle (Figure 2B). Diagnostic yields are greater than 90%, although randomized trials against standard TBNA are required. In patients with proven or suspected lung cancer and ‘nonbulky’ nodal enlargement greater than 1 cm on computed tomography scan, EBUS TBNA was found to have a sensitivity of 94.6% (6) with a similar sensitivity of 92.3% in a study of patients with nodes less than 1 cm (7). EBUS is more sensitive and more specific than positron emission tomography scanning for mediastinal staging in lung cancer (8). EBUS has been compared with mediastinoscopy for lung cancer staging (9), and EBUS TBNA is superior to blind TBNA for the investigation of sarcoidosis (10).

CONCLUSION

EBUS offers a new safe, minimally invasive and highly sensitive option for our patients. In our institution, over one-half of flexible bronchoscopies include an EBUS component. Clinicians will need to ensure a relatively large procedure volume to ensure that they attain and maintain competency with this exciting technique.

REFERENCES


End of life issues in chronic obstructive pulmonary disease

Paul Hernandez MDCM FRCPC
Respirology Division, Department of Medicine, Capital District Health Authority, Dalhousie University, Halifax, Nova Scotia
E-mail paul.hernandez@cdha.nshealth.ca.

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality in Canada and the only leading cause of mortality on the rise, particularly among women (1). Despite recent advances in our understanding of COPD pathophysiology and management, many patients suffer considerable physical and psychological burden related to COPD. The present paper will review the prognostic factors for mortality, the determinants of quality end-of-life care, and management options to improve end-of-life care in advanced COPD.

The natural history of COPD is unpredictable in individual patients, rendering the timing of discussions about end-of-life care challenging. Many family physicians report being ill prepared for this communication task (2). Recent studies have improved our ability to predict short term survival (3-5), and
predictors of mortality are summarized in Table 1. Patients with these risk factors should be engaged in discussions about prognosis and end-of-life care.

**TABLE 1**

**Predictors of chronic obstructive pulmonary disease mortality**

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very severe airflow obstruction (eg, forced expiratory volume in 1 s less than 30% predicted) and hyperinflation (eg, inspiratory capacity/total lung capacity less than 25%)</td>
<td></td>
</tr>
<tr>
<td>Poor functional status (eg, Medical Research Council score 4 to 5)</td>
<td></td>
</tr>
<tr>
<td>Poor exercise tolerance (eg, 6 min walk distance less than 150 m)</td>
<td></td>
</tr>
<tr>
<td>Poor nutritional status (eg, body mass index less than 19 kg/m²)</td>
<td></td>
</tr>
<tr>
<td>Older age</td>
<td></td>
</tr>
<tr>
<td>Recurrent acute exacerbation of chronic obstructive pulmonary disease (especially requiring hospitalization and mechanical ventilation)</td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td></td>
</tr>
</tbody>
</table>

Recent studies using qualitative methodologies have assessed the experiences of patients living and dying with advanced COPD (6-9). Patients report a loss of dignity related in part to over-reliance on others, and a desire to avoid unnecessary life prolongation, to minimize the burden on their loved ones, and to have adequate time to put their affairs in order. Symptom control, particularly dyspnea, is often suboptimal. Unfortunately, these patients often spend much of their last year of life in hospital rather than at home.

A recurrent theme in research about end-of-life care is the importance of good communication. Only a minority of patients with advanced COPD discuss treatment preferences for end-of-life care with their physicians, even in supportive, multidisciplinary settings such as pulmonary rehabilitation (10,11). Curtis(12) has provided excellent guidance for talking about end-of-life care, prognosis and advanced care planning. Discussions should include patient preferences for life-sustaining treatment options and choice of surrogate decision makers. Patients and families should be aware that withholding life sustaining measures does not equate to withholding all care, or abandonment.

One possible solution to improve end-of-life care of COPD is to involve formal palliative-care services. Palliative care aims to relieve the suffering and improve the quality of life of persons who are living with or dying from advanced illness, or are bereaved (13). Symptom relief is an important objective of palliative care. Discussions should include patient preferences for life-sustaining measures does not equate to withholding all care, or abandonment.

Although feelings of anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD), estimates of their prevalence vary considerably (1). This likely reflects the variety of scales and methods used to measure such symptoms. Regardless of whether anxiety and depression are considered separately or as a single construct, their impact on COPD patients is important.

Anxiety and depression in end-stage chronic obstructive pulmonary disease

Yves Lacasse MD MSc FRCPC
Unité de recherche en pneumologie, Centre de recherche de l’Hôpital Laval, Institut universitaire de cardiology et de pneumologie de l’Université Laval, Québec
E-mail Yves.Lacasse@med.ulaval.ca

Although feelings of anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD), estimates of their prevalence vary considerably (1). This likely reflects the variety of scales and methods used to measure such symptoms. Regardless of whether anxiety and depression are considered separately or as a single construct, their impact on COPD patients is important.

Some of the specific anxiety-related disorders include generalized anxiety disorder, panic attacks and panic disorder. A heightened experience of dyspnea is likely to be a contributing factor to anxiety. Feelings of depression in COPD have been described as reactive to the condition and symptoms may range from an ‘adjustment disorder with depressed mood’ to ‘major depression’. Depression may be precipitated by the loss and grief associated with the disability of COPD. Smoking has been associated with nicotine addiction and the factors that contribute to
smoking may also predispose to anxiety and depressive disorders.

With the increasing awareness of the high prevalence and impact of anxiety- and depression-related symptoms in patients with COPD, it is interesting to note that these psychological manifestations are treated in a minority of patients. Randomized controlled trials indicate that exercise training and carefully selected pharmacology are often effective in ameliorating anxiety and depression.

When depressive symptoms are identified in hospitalized patients, the prognosis is usually good, with these symptoms usually remitting within 12 weeks. However, only one-quarter of those with major depression remit by 12 weeks and only one-half by 24 weeks.

Every clinician caring for patients with COPD must have a high level of suspicion regarding the presence of anxiety and depressive symptoms as well as the possibility of a major anxiety or depressive disorder. Although respiratory specialists usually focus on the physiological aspects of the disease, they often have access to rehabilitation programs in which a psychological assessment can be conducted. Referral to a mental health professional is indicated when high levels of anxiety or depression are suspected using simple diagnostic screening instruments; anxiety or depression are refractory to pharmacological or nonpharmacological therapy; the choice of anxiolytic or antidepressant drug is complicated by concurrent medications or comorbidities; or the patient presents with suicidal ideation.

An understanding of the patient’s psychological history and coping mechanisms and the role of anxiety and depressive reactions to illness may enable clinicians to reduce these symptoms and to improve quality of life among patients with COPD.

CONFLICTS OF INTEREST: None.

REFERENCES

**Is chronic obstructive pulmonary disease really a cardiac disease?**

Don D Sin MD
The University of British Columbia (Respiratory Division), The Providence Heart and Lung Institute & The James Hogg icAPTURE Center for Cardiovascular and Pulmonary Research (St. Paul’s Hospital), Vancouver, British Columbia
Email dsin@mlr.ubc.ca

**EPIDEMIOLOGY**

Cardiovascular diseases (CVDs) such as ischemic heart disease, sudden deaths, and heart failure are common causes of hospitalization and mortality in patients with chronic obstructive pulmonary disease (COPD). In patients with mild to moderate severity, CVDs are the leading cause of hospitalization (50% of hospital admissions) and the second leading cause of mortality, after lung cancer (1). COPD patients have twice the risk of CVD hospitalization and mortality than subjects without COPD (2). The risk is increased in a dose-dependent way within the range of forced expiratory volume in 1 s values that are considered in the ‘normal’ range (ie, between 80% to 100% predicted) (2).

In severe and very severe COPD, respiratory failure and pneumonia are the leading causes of morbidity and mortality (3). However, even in these patients, CVDs are a significant concern. Approximately 20% to 25% of all deaths in patients with GOLD stages 3 and 4 disease are principally related to a cardiovascular event (3). Having a previous history of CVD increases the risk of mortality by 2.5-fold and the risk of a COPD hospitalization by 35%, independent of other risk factors. In the general population, reduced lung function is a major risk factor for CVD mortality and may contribute up to 25% of the total attributable risk for ischemic heart disease mortality (4).

**MECHANISM**

Inflammation plays a central role in the pathophysiology of COPD (5). Although cigarette smoking causes inflammation in the small airways of all smokers, most do not develop clinically relevant COPD (5). Once COPD becomes established, airway inflammation persists even after smoking cessation (5). COPD patients also have systemic inflammation, characterized by elevated plasma C-reactive protein (CRP) and fibrinogen (6). This rise in biomarkers parallels the rise in airway inflammation, suggesting a link between them.

Elevated plasma CRP has been associated with CVD morbidity and mortality in patients with COPD as well as in the general population. In a large group of smokers with mild to moderate COPD (Lung Health Study [6]), serum CRP levels predicted the risk of all-cause and CVD mortality. The highest compared with the lowest quintile of CRP was associated with a 51% increase in fatal and nonfatal CVD (6).

Hemostatic and thrombotic factors also play a role in CVD morbidity and mortality of COPD patients, with increased thrombin, tissue plasminogen activator-plasminogen activator inhibitor complex and beta-thromboglobulin (a marker of platelet activation). A large meta-analysis has shown that for every 1 g/L increase in plasma fibrinogen, the risk of COPD-specific and CVD-specific mortality increase by fourfold and 2.4-fold, respectively (7). During exacerbations, plasma fibrinogen increases further, which contributes to the abnormal hemostasis and thrombosis.

Increased sympathetic tone in COPD increases the risk of CVDs by increasing arterial pressure, inducing endothelial dysfunction, and promoting cardiac remodelling. In advanced COPD, patients demonstrate excess adrenergic tone, which appears to be related to the patients’ oxyhemoglobin saturation.

**TREATMENT**

Smoking cessation is the most important intervention in reducing CVD mortality (1). Compared with continuing smokers, sustained quitters have a 65% reduction in the risk of death from CVD. Even intermittent quitters experience a large reduction in the risk of death from CVD (Approximately 54% relative reduction compared with continuing smokers). Whether drug treatments modify CVD risk in COPD is controversial. Observational studies and one post hoc analysis suggests that inhaled corticosteroids (ICSs) reduce CVD, and a recent trial noted a lower all-cause mortality among patients treated with a ICS/long-acting beta-2 agonist combination compared with a long-acting anticholinergic bronchodilator.
(9), driven by lower rates of CVD events in the ICS/long-acting beta-2 agonist group although mortality rates were low in both groups.

CONCLUSION
COPD patients have twice the risk of CVD events compared with the general population. Smoking cessation reduces CVD risks and certain pharmacological therapies may modulate risk, pending results from large clinical trials.

ACKNOWLEDGEMENTS: DDS is a Senior Scholar with the Michael Smith Foundation for Medical Research and a Canadian Research Chair in COPD. The work is supported in part by the Canadian Institutes of Health Research and the GlaxoSmithKline/St Paul’s Hospital Foundation Professorship in COPD.

CONFLICT OF INTEREST: DDS has received research funding and honoraria for speaking engagements from GlaxoSmithKline and AstraZeneca, makers of ICS/long-acting beta-2 agonist drugs.

REFERENCES

Action plans in asthma: Knowledge, confusion and controversy
Lisa Cicutto PhD CAE
National Jewish Health, Denver, Colorado, USA
E-mail lisa.cicutto@utoronto.ca

Since 1980, written asthma action plans have been discussed and evaluated as an important element of asthma care (1). Currently, provision of an action plan is a core recommendation of asthma practice guidelines (2,3), although usage rates remain between only 2% and 11% (4-6).

The definition and concept of written asthma action plans has evolved over the past 20 years. Earlier action plans were described as “written instructions for what to do and when for the treatment of asthma” (7), focusing primarily on identifying warning signs of worsening asthma and the appropriate pharmacological approach to their treatment. More recently, the Alberta Asthma Action Plan Task Force defined an asthma action plan as “written pharmacologic and non-pharmacologic instructions that are guided by action points, developed collaboratively between the patient and health professionals” (4). In general, written asthma action plans consist of zones to indicate various levels of asthma control with corresponding action points or steps that the patient needs to follow. The most common format is a three-zone plan that uses a traffic control analogy, where the green zone indicates stability, the yellow zone indicates caution and a need to increase therapy, and the red zone indicates danger and a need for urgent medical assistance.

Several systematic reviews of studies of action plans have identified areas of strong evidence as well as areas of controversy. Gibson et al’s original systematic review (8) and subsequent updates indicate that those who receive asthma self-management education, visit the doctor regularly and have a written asthma action plan experience fewer urgent visits to the emergency room and physician, hospital admissions, nocturnal awakenings and missed days of work. However, a systematic review by Toelle et al (9) observed that action plans alone do not improve adherence to maintenance therapy and do not consistently produce better patient outcomes than no written plan at all. The authors concluded that the contribution of an action plan to the known beneficial effects of a comprehensive asthma care program (self-management education and regular review) is unknown. However, a recent review in children (10) suggests that a written action plan compared with no written action plan can lead to fewer acute care visits, school absences and nocturnal awakenings, although this was based on a single randomized controlled trial.

Systematic reviews have also focused on identifying key characteristics of the most effective asthma action plans. In adults, current evidence suggests that action plans based only on symptoms perform similarly to those that include peak expiratory flow (10,11). However, in children, symptom-based plans lowered the risk of an exacerbation requiring an acute care visit, and children preferred these type of plans (10). The most effective action plans use two to four action points and recommend inhaled and oral corticosteroids for treatment of exacerbations (12).

Overall, evidence suggests that action plans supported by self-management education and regular follow-up improve clinical outcomes (8,9,11). However, there are many areas that require future research, such as assessing the actual use and timing of behaviours in action plans; exploring action plans in various subgroups (according to gender, culture, language, literacy level) and settings (schools, daycares, emergency departments); and identifying interventions to improve the uptake of written action plans by practitioners and patients.

CONFLICTS OF INTEREST: None.

REFERENCES

Preliminary results of a home telecare project for patients with chronic obstructive pulmonary disease  
Antonia Arnaert PhD MPA MSC RN1, Megan Wainwright BA2  
1School of Nursing; 2Department of Oncology, McGill University, Montreal, Quebec  
E-mail antonia.arnaert@mcgill.ca

Chronic obstructive pulmonary disease (COPD) is a major public health problem (1,2), particularly in older patients (3,4). Although reasons for hospitalizations vary due to comorbidities (5), acute exacerbations are the main cause, and result in poor quality of life (6) and increased costs (7,8). Studies have found that increased nursing home care can help COPD patients to cope better and, in some cases, can reduce hospital admissions (9). One strategy to improve homecare services is to wean them off the HTC system. The Living Well with COPD™ action plan (11), for which the nurses received training, guided the nurses’ care plan.

This three-month feasibility study was the first in Quebec to use remote monitoring coupled with video visits. The aim was to test the HTC technology, become familiar with the needs of COPD patients, evaluate our methods, and explore nurse and patient perspectives. In January 2008, three female patients (mean age 70 years) with severe COPD were recruited while they were being treated at the McGill University Health Centre for an acute exacerbation. Approximately one week following discharge, they began receiving HTC visits from a trained tele-nurse. The HTC system is a Web-based application that runs on desktop computers (Figure 1). Most aspects of the system are controlled remotely by the nurse, including the devices for monitoring patients’ vital signs, such as blood pressure and blood oxygen. During the first two months, patients were each scheduled for a daily visit, and the third and final month was used to wean them off the HTC system. The Living Well with COPD™ action plan, for which the nurses received training, guided the nurses’ care plan.

The total number of HTC visits made during the study was 161, lasting on average 15.1 mins, which is consistent with other HTC studies (12). Nurses’ and patients’ experiences were extremely positive; however, the primary challenge in the first weeks of the study was helping the patients to adapt to and become comfortable with the technology. With regard to HTC’s potential to encourage self-management, the following statement summarizes the point of view of the nurses:

“`Theoretically they [patients] did understand...however once they started to have symptoms...the theory I thought sometimes went out the window and the emotions took over...and then they got a bit lost ‘what should I do, I think I should wait’...That’s where I thought our intervention was helpful because they started to make the connection between what they knew and the emotions. After about six weeks receiving HTC, all of a sudden we [nurses] didn’t have to remind them so much ‘maybe I should start my action plan’, there you go, that is a good idea! And then you reinforce it.”`

All patients said that they greatly enjoyed the daily contact and support from the nurses and that it reassured them to have their vitals checked. One patient said:  
“I found it [HTC] fantastic! It helped me know myself and to no longer wait before going to the hospital. It

Figure 1. Home telecare patient station: desktop computer, Webcam, blood-pressure cuff, microscope, stethoscope, blood oximeter, scale and PHD Medical’s (Canada) Televisit software. Not included in image: thermometer.
helped me have more confidence in myself, and control my fears, my breathlessness and my exacerbations, it was incredible for me...the nurses would advise me first 'don't you think you should call your doctor?' and after a while I learned to know myself, to know it's faster than I thought. I had a tendency of waiting, waiting…it will pass, it will pass, and it doesn’t'.

The present study demonstrates HTC’s potential for monitoring exacerbations and for assisting patients in applying the skills and techniques learned for managing their disease at home. It is our belief that HTC may very well be the missing link for COPD self-management education.

ACKNOWLEDGEMENTS: We would like to thank Ms Donna Byrne MscN, the President of the private homecare company Health Access Santé in Beaconsfield, Quebec, for her tremendous infrastructural and financial support and thank her homecare nurses for participating in this study. We also thank the COPD network case manager of the referring hospital, the COPD nurse of the pulmonary rehabilitation clinic and the technology provider PHD Medical for their collaboration and contribution. The research was funded by GRISIM (Groupe de recherché interuniversitaire en science infirmière de Montréal) and Training and Human Resources Development Project, Health Canada.

CONFLICTS OF INTEREST: None.

REFERENCES

Does obstructive sleep apnea cause cardiovascular disease?

Najib T Ayas MD MPH, Joshua Wenner BA
Respiratory Division and Sleep Disorders Program, University of British Columbia, Vancouver, British Columbia
Email Najib.ayas@vch.ca

Obstructive sleep apnea (OSA) is a respiratory disorder characterized by reduced upper airway patency during sleep leading to recurrent episodes of airflow cessation (apnea) or reduction (hypopnea), resulting in sleep fragmentation and hypoxemia. There is accumulating evidence that OSA is a cause of cardiovascular disease.

First, there are a number of animal studies that have demonstrated a potential link between experimentally induced intermittent hypoxia and the development of cardiovascular disease. For example, in a recent study, investigators exposed 40 mice to one of four conditions for 12 weeks: intermittent hypoxia and a high cholesterol diet; intermittent hypoxia and a normal diet; intermittent air and a high cholesterol diet; and intermittent air and a normal diet (1). Aortic plaques were identified in nine of 10 mice in the intermittent hypoxia and high cholesterol group, but in none of the mice in the other groups. Furthermore, increased levels of lipids and markers of hepatic inflammation were found in this group, suggesting that inflammation may be a potential pathogenic mechanism.

Second, OSA is strongly and independently associated with cardiovascular disease in a number of prospective cohorts. For example, Marin et al (2) followed five groups of men (healthy men, snorers without OSA, untreated patients with mild/moderate OSA, untreated patients with severe OSA, and treated patients) for 10 years to track the incidence of cardiovascular disease (stroke, myocardial infarction, percutaneous coronary intervention, coronary artery bypass). Compared with healthy controls, untreated men with severe OSA had a threefold increased risk of fatal (OR=2.87, 95% CI 1.17 to 7.51) and nonfatal (OR=3.17, 95% CI 1.12 to 7.51) cardiovascular events, even after controlling for a variety of potential confounders. Interestingly, the OR was not significantly increased in patients treated for OSA, suggesting that treatment may substantially mitigate the increased risks associated with the disease. A number of other prospective cohorts have also demonstrated independent associations between OSA and a variety of cardiovascular and cerebrovascular outcomes (3-7). However, a major problem with these studies is the influence of potential confounding variables.

Third, experimental studies of patients with OSA treated with continuous positive airway pressure (CPAP) have demonstrated reductions in a variety of cardiovascular risk markers including blood pressure, systemic inflammation and endothelial dysfunction (8-10). A recent small preliminary report (11) suggested improvements in carotid intima and media thickness with CPAP.

Animal studies, prospective epidemiological studies, and short-term CPAP intervention studies have provided compelling data implicating OSA in the pathogenesis of cardiovascular disease. However, large, long-term, randomized controlled trials of CPAP therapy are needed to understand whether therapy reduces risks of cardiovascular disease in patients with OSA. These types of studies will be crucial to our understanding of the
CONFLICTS OF INTEREST: Dr Ayas has received a research grant from Respironics Inc.

REFERENCES


Diagnostic strategies for patients with suspected sleep-disordered breathing

R John Kimoff MD FRCP
Respiratory Division, McGill University Health Centre and Meakins-Christie Laboratories, McGill University, Montreal, Quebec
E-mail john.kimoff@mcgill.ca

Obstructive sleep apnea (OSA) is estimated to affect 4% of adult women and 9% of adult men, based on data gathered in the early 1990s (1). With the dramatic increase in obesity over the past two decades in North America (2), the true prevalence of OSA is likely now even higher. OSA is associated with considerable morbidity and likely increased mortality, representing a major public health issue.

Traditionally, the gold standard approach to diagnosis of OSA has been sleep laboratory-based polysomnography (3), with subsequent polysomnographic recording to manually titrate nasal continuous positive airway pressure (CPAP), the proven treatment of choice for OSA (4). However, polysomnography is an expensive procedure with limited availability in many parts of Canada, and there is growing evidence that alternative, lower-cost strategies such as portable monitors can play a role in OSA management (5,6). In patients with a moderate to high pretest probability of OSA, such devices can often establish the presence and severity of disease and inform the selection of treatment. A major evidence review (6) concluded that the increased accuracy of polysomnographic apnea-hypopnea index measurements, compared with ambulatory monitors, does not provide superior prediction of clinically relevant outcomes such as CPAP response or compliance, among patients with a high probability of OSA.

However, even once a diagnosis of OSA is made, access to nasal CPAP is limited. Only Ontario, Manitoba and Saskatchewan have universal CPAP coverage programs, and requirements for polysomnographic CPAP titration may still result in long waiting times. Other provinces and territories have widely varying degrees of support for and access to CPAP. Several studies have demonstrated that autotitrating CPAP can guide initiation of effective treatment on an ambulatory basis as reliably as polysomnographic CPAP titration in moderate to severe OSA (7,8). Recently, Mulgrew et al (9) demonstrated that in patients with a high probability of OSA, ambulatory diagnosis and treatment with autotitrated CPAP produced equal or superior treatment compliance and improvements in excessive daytime sleepiness to conventional polysomnography. These studies suggest that ambulatory disease management with portable diagnostic testing and auto-CPAP titration can be effective in moderate to severe OSA.

Generalizability is limited by the fact that the majority of studies to date have focused on middle-aged Caucasian males without major medical comorbidities presenting with a strong clinical history for OSA. There is a need for further research among diverse ethnic groups, women, the elderly, patients with major comorbidities, and in screening and prevention in the general population. A Workshop on Research Priorities in Ambulatory Management of OSA was held in October 2007, and its key findings and recommendations will be published in the Proceedings of the American Thoracic Society. This document should serve as a blueprint for the generation of new knowledge in this area.

It is now clear that ‘uncomplicated’ moderate to severe OSA does not absolutely require, and due to sheer volume, cannot solely be managed by, tertiary medical centres. However, practical impediments remain to the translation of even current knowledge on ambulatory management of OSA into widespread, effective use in primary care and other settings. Clinical guidelines on the role of portable monitors in OSA management (10) emphasize the need for trained, expert medical and technical staff to ensure competent clinical evaluation and high-quality recording, data analysis and interpretation. Currently, there is a major lack of such skilled personnel in Canada. However, partnerships between specialized and primary centres may enable training and protocols for quality assurance in OSA diagnosis and management. Ambulatory technology could then be provided in the primary setting, with referrals to specialized centres for more complex cases. While considerable further work is needed to identify optimal, cost-effective methodologies, it will only be through the development of integrated networks of this nature that high-quality care for OSA will become accessible to all Canadians.
CONFLICTS OF INTEREST: Dr Kimoff has received speaker fees for presentations on sleep apnea from GlaxoSmithKline and VitalAire Inc.

REFERENCES:

Canadian Thoracic Society guidelines for sleep disordered breathing
John A Fleetham
Respiratory Division, University of British Columbia, Vancouver, British Columbia
E-mail John.Fleetham@vch.ca

Sleep disordered breathing (SDB) is associated with reduced quality of life, decreased cardiovascular health, and increased health care utilization, motor vehicle crashes and mortality. There are several well tolerated and effective treatments that have been shown to improve these various outcomes. Despite this, the majority of Canadians with SDB remain undiagnosed and untreated. There is considerable variability in access to diagnosis and treatment for SDB across Canada, which has led to a heterogeneous approach across provinces and territories. In an attempt to address this, the Canadian Thoracic Society has developed national guidelines for the diagnosis and treatment of SDB (1,2). These guidelines include recommendations concerning patient triage (Table 1) and maximum wait times for assessment (Table 2). Patients with suspected SDB should be triaged based on the degree of subjective sleepiness and the presence of comorbid disease, a safety critical occupation, risk of a motor vehicle crash and sleep arterial oxygen desaturation. Urgent patients should have a medical specialist assessment and/or polysomnography and completed within two to four weeks, and all patients, within six months.

As with any medical condition, the diagnosis of SDB starts with history and physical examination. Sleep monitoring is required to confirm the diagnosis and to determine the type and severity of SDB. There is much debate about the most appropriate form of sleep monitoring. Level I (complete laboratory polysomnography) remains the accepted standard for evaluation of SDB and is the test of choice. There is, however, quite variable access to polysomnography across Canada. Level II (full ambulatory polysomnography) and Level III (portable monitoring with multichannel cardiorespiratory recording devices) can be used to confirm the diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) in patients with a moderate to high pretest probability, but are of more limited use in patients with comorbid disease and for the diagnosis of other forms of SDB. Studies using Level IV portable monitoring (oximetry) may have a role in the initial assessment of SDB; however their significant limitations in distinguishing different types of SDB must be fully appreciated before using them to make diagnostic and therapeutic decisions. Although access to polysomnography across Canada is improving, it is unlikely to increase sufficiently to provide timely access to diagnosis of SDB for all Canadians. A diagnostic approach

**TABLE 1**
Triage criteria for patients referred for assessment of sleep disordered breathing (SDB)

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urgent</strong></td>
<td>Patients with: suspected SDB; major daytime sleepiness (ESS 15 or greater); and a safety-critical occupation†</td>
</tr>
<tr>
<td>Or</td>
<td>suspected SDB plus one or more of the following: • comorbid disease* or pregnancy • overnight home oximetry that reveals &gt;30/h 4% desaturations</td>
</tr>
<tr>
<td><strong>Semiurgent</strong></td>
<td>Patients with: suspected SDB; major daytime sleepiness (ESS 15 or greater); and no comorbid disease*, pregnancy or safety-critical occupation†</td>
</tr>
<tr>
<td><strong>Elective</strong></td>
<td>Patients with: suspected SDB; no major daytime sleepiness (ie, ESS &lt;15); no comorbid diseases or pregnancy; and no safety-critical occupation†</td>
</tr>
</tbody>
</table>

*Comorbid disease: ischemic heart disease, cerebrovascular disease, congestive heart failure, obstructive/restrictive lung disease, pulmonary hypertension, hypercapnic respiratory failure. †Safety critical occupations or at high risk of a motor vehicle crash: Individuals working with machinery, or employed in hazardous occupations; truck, taxi, bus drivers; railway engineers, airline pilots, ship captains; car drivers who admit to have fallen asleep while driving within the last two years. ESS Epworth Sleepiness score

**TABLE 2**
Maximum wait times for medical specialist assessment and/or polysomnography

<table>
<thead>
<tr>
<th>Category</th>
<th>Wait Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Urgent cases</strong></td>
<td>within 2 to 4 weeks</td>
</tr>
<tr>
<td><strong>Semi-urgent cases</strong></td>
<td>within 2 months</td>
</tr>
<tr>
<td><strong>Elective cases</strong></td>
<td>within 6 months</td>
</tr>
</tbody>
</table>

**REFERENCES:**
RSV INFECTION AND RESPONSE

Primary infection occurs once the virus invades the airway epithelium of a susceptible host. It is the host response that leads to RSV disease in a predictable fashion including initial innate responses, followed by cellular-specific responses and, finally, humoral immunity. The timing of the host immune response is important; the innate response, including release of chemokines and cytokines, occurs within the first three days. During this time, T-cells, neutrophils, monocytes and in some, eosinophils, are attracted, along with upregulation of adhesion molecules and dendritic cell activation. Following this, cell-mediated responses occur with either a T helper cell (Th)1 or a Th2 response. Most infants and children will mount a Th1-type response to RSV infection and have resolution of disease. However, in predisposed individuals, a Th2 response to RSV infection may occur, leading to enhanced disease and severe bronchiolitis and in some, subsequent long term sequelae.

RSV DISEASE

Even though most children are infected by their first birthday, some infants are at risk for significant disease: those born prematurely, those with either pulmonary or cardiac disease, and those with immune impairment. Approximately 3% of children with RSV disease are admitted to hospital and of those, 10% die. It is important to realize that RSV infection does not correlate with disease severity or progression; often, the virus is cleared at the height of maximal symptoms. The symptoms are clearly related to the individual host response and ensuing airway pathology: mucosal edema, mucus production, bronchospasm, airway blockage leading to patchy atelectasis and compensatory emphysema. The younger infant is at higher risk for disease; an immature immune system despite maternally derived antibodies does not confer full protection, humoral responses are often inconsistent, and the youngest infants may actually mount a Th2 rather than a Th1 response to infection, resulting in increased morbidity in this population.

SUMMARY

RSV is common in infancy and the disease is associated with host response rather than viral load. Immaturity of the infant response to infection may lead to a Th2 cell mediated response (instead of a Th1 response), which leads to increased morbidity and long term sequelae.

REFERENCES


Inflammatory response to viral infection in children: Focus on respiratory syncytial virus

Brenda-Louise Giles
University of Manitoba Children’s Hospital, Winnipeg, Manitoba
E-mail gilesbl@cc.umanitoba.ca

Respiratory syncytial virus (RSV) is responsible for the majority of lower respiratory tract infections in infancy. Infection with RSV is seasonal in temperate climates close to the poles, is yearly in equatorial regions, and has a worldwide distribution. In Canada, RSV disease typically occurs during the winter months, in a predictable fashion. Most children acquire their primary RSV infection by one year of age, and almost all children have been infected by their second birthday.

RSV is the most common pathogen leading to hospitalization in infancy, despite the presence of maternally derived circulating antibodies. Furthermore, humoral antibody-derived immunity is incomplete, rendering one susceptible to repeated infections over a lifetime.
Inflammatory response to viral infections in adults

David Proud PhD
Airway Inflammation Group, Institute of Infection Immunity and Inflammation, University of Calgary, Calgary, Alberta
E-mail dproud@ucalgary.ca

Upper respiratory viral infections are a major trigger for acute exacerbations of asthma and chronic obstructive pulmonary disease. Although several viral types have been associated with exacerbations of these diseases, in both adolescents and adults human rhinovirus (HRV) is the dominant pathogen detected (1). The epithelial cell is the primary site for HRV infection, and there is now strong evidence that infections from the upper airway can spread to lower airway epithelial cells (2). HRV does not induce overt cytotoxicity in epithelial cells. Thus, it is generally assumed that an over-exuberant host inflammatory response to viral infection, initiated by alterations of epithelial cell biology, triggers disease exacerbations. To examine this concept, investigators have combined in vitro studies of cultured human airway epithelial cells with in vivo studies in experimental, or naturally acquired, HRV infections. Infection of cultured human epithelial cells with HRV has been shown to lead to generation of a variety of proinflammatory chemokines, including interleukin (IL)-8 (CXCL8), epithelial-neutrophil activating peptide (ENA)-78 (CXCL5), and interferon-γ-inducible protein of 10 kd (IP-10, CXCL10), as well as cytokines, such as IL-1β, IL-6, granulocyte monocyte colony-stimulating factor and IL-11 (1,3). Importantly, several of these products also are detected in airway secretions during HRV infections in vivo, suggesting that they may contribute to recruitment and activation of inflammatory cells (1,3). Viral exacerbations of asthma and chronic obstructive pulmonary disease are characterized primarily by increased numbers of neutrophils and lymphocytes (Figure 1). The chemokines IL-8 and ENA-78 are potent recruiters of neutrophils, and IL-8 levels correlate with neutrophil counts in both adults and children (4). Similarly, IP-10 is a potent chemoattractant for natural killer cells and type 1 lymphocytes, and IP-10 levels correlate with lymphocyte numbers during in vivo HRV infections. HRV infections also stimulate epithelial production of human β-defensin 2, which could serve as a link between the innate and adaptive immune responses by recruiting immature dendritic cells to sites of infection (5).

Figure 1: Infection of epithelial cells with human rhinovirus (HRV) may induce both inflammation and remodeling. Production of interleukin (IL)-1 will activate vascular endothelium, increasing vascular permeability and the generation of ‘secondary’ mediators. Release of chemokines such as IL-8 and epithelial-neutrophil activating peptide-78 (ENA-78) will recruit and activate neutrophils, while interferon-γ-inducible protein of 10 kd (IP-10) will recruit type 1 lymphocytes. Mediators released from the cells can contribute to perpetuation of infection. Production of human β-defensin-2 (HBD-2) can recruit and activate dendritic cells and could initiate antigen presentation. On the other hand, production of mediators such as transforming growth factor-β (TGF-β), activin A and amphiregulin may stimulate matrix protein production from fibroblasts and myofibroblasts, while vascular endothelial growth factor (VEGF) may contribute to angiogenesis.

Although production of cytokines and chemokines from epithelial cells may be the initial trigger for enhanced inflammation, cytokines such as IL-1β would be expected to cause vascular activation and release of plasma mediators (Figure 1). Indeed, bradykinin and lysyl-bradykinin are produced during HRV infections and correlate with symptoms, but defining the role of these peptides needs specific intervention studies. Similarly, recruited inflammatory cells can release a ‘second wave’ of mediators that may contribute to airway inflammation and mucus production. In children, infection with respiratory syncytial virus (RSV) induces production of leukotrienes (6). These likely contribute to airway symptoms, because infants hospitalized for RSV bronchiolitis showed a small but significant inhibition of postbronchiolitis lower airway symptoms in response to montelukast. Moreover, montelukast reduced the number of virally induced asthma exacerbations in young children with intermittent asthma (7). In adults, modest leukotriene production has been reported in subjects infected with RSV or influenza, but not during HRV infections.
In addition to the role of HRV-infected epithelial cells in airway inflammation, recent evidence suggests that they also produce a range of growth factors that may be expected to contribute to airway remodelling (8). Given that children get multiple infections annually in early life, these may contribute to remodelling seen in young children, while in adults, viral infections may contribute to continued progression of remodelling (Figure 1). Finally, epithelial cells may help regulate susceptibility to development of disease exacerbations via their ability to release antiviral agents, such as nitric oxide, that reduce viral inflammation and viral replication (9). This raises the possibility that boosting such antiviral defenses may be of therapeutic potential.

CONFLICTS OF INTEREST: None.

REFERENCES

**Limb muscle dysfunction in chronic obstructive pulmonary disease**

François Maltais MD
Centre de pneumologie, Hôpital Laval, Sainte Foy, Quebec City, Quebec
E-mail francois.maltais@med.ulaval.ca

HIGHLIGHTING THE IMPACT OF LOWER LIMB MUSCLE DYSFUNCTION ON EXERCISE TOLERANCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND HOW THIS MAY APPLY TO PHARMACOTHERAPY AND REHABILITATION

Bronchodilation and exercise tolerance
Clinical trials confirm the efficacy of long-acting bronchodilators in reducing operational lung volumes during exercise, reducing dyspnea and increasing exercise tolerance (1-3). However, improvement in lung function correlates weakly with changes in exercise capacity and for some patients, exercise capacity does not change (4).

Leg fatigue during exercise
Leg fatigue is the predominant limitation at peak cycling exercise in one-third of patients with chronic obstructive pulmonary disease (COPD) (5), and contractile fatigue of the quadriceps with cycle-based exercise has been demonstrated (6). Contractile fatigue occurs at a much lower exercise intensity in COPD compared with healthy individuals (7). Such patients are vulnerable to fatigue, even during mild exercise.

To evaluate whether contractile fatigue of the quadriceps could influence exercise tolerance, 18 patients with COPD exercised at a constant work rate to exhaustion on two separate days (7). Exercise was preceded by nebulized placebo or ipratropium bromide. Using magnetic stimulation of the femoral nerve, the strength of the quadriceps was measured before and after exercise. One-half of the 18 patients developed contractile fatigue of the quadriceps, with reduced muscle strength greater than 15%. In patients who did not develop fatigue, a 13% improvement in forced expiratory volume in 1 s after bronchodilation translated into better exercise endurance. A similar improvement in forced expiratory volume in 1 s did not influence exercise in patients who developed quadriceps fatigue. Therefore, leg fatigue modulates the exercise-response to bronchodilation.

This observation is supported by a pooled analysis of three studies (5,8,9) of exercise response to bronchodilation in patients with COPD. In this analysis, the improvement in exercise was smaller in those limited by leg fatigue than those limited by dyspnea.

Susceptibility to muscle fatigue
Muscle weakness commonly contributes to muscle fatigue in COPD (10,11) and the perception of leg fatigue for a given power output is greater in weak compared with strong individuals. Quadriceps strength is a determinant of exercise capacity independent of the impairment in lung function.

Morphometric changes, such as a reduction in highly oxidative type I fibres in favour of fatigue-susceptible type IIx fibres, predispose patients to fatigue (8,12), and quadriceps mitochondrial enzyme activity is diminished in COPD compared with healthy controls (13). Muscle capillarization is also affected (14).

Treating peripheral muscle dysfunction in COPD
Peripheral muscle dysfunction is improved with exercise training, with both aerobic and strengthening exercises (15,16) reported to increase mid-thigh muscle area and muscle strength (15). The aerobic capacity of the quadriceps improved following a 12-week training program of three weekly 30 min to 40 min exercise sessions (17). Other benefits included a slower rise in blood lactate during exercise (18) and a reduced susceptibility to fatigue (19).

Exercise training also alleviates the central component of exercise intolerance in COPD. In fact, a reduced ventilatory requirement at a given exercise level was one of the first physiological adaptations following exercise training in COPD to be reported (18). As a result, exercise-induced dynamic hyperinflation is diminished (20).

An example of the synergistic interactions between pharmacotherapy and rehabilitation was noted when patients with COPD were randomized to receive tiotropium or placebo before undertaking an eight-week exercise training program (21). The
combined treatment group had a larger improvement in exercise endurance during the training program compared with the group randomized to exercise training alone, perhaps because optimal bronchodilation enabled higher training intensities.

How to optimize the benefits of pulmonary rehabilitation

As high training intensity is unrealistic for many patients limited by severe dyspnea, adjunct approaches include oxygen supplementation (22), heliox (23), noninvasive ventilation (24) and interval training (25), although their long-term implications on exercise, functional status and quality of life remain to be defined.

Treatment of muscle wasting by combining strengthening exercises with high doses of anabolic steroids in men with COPD and low testosterone levels was associated with a striking gain of 3.3 kg in limb muscle mass over a 12-week period (26). The longer term relevance of this approach, as well as other anabolic substances, is unclear.

Implications of limb muscle dysfunction for the choice of exercise testing

Because quadriceps fatigue during exercise is worse after cycling than after walking (5,27), tests such as the endurance shuttle walk should be appropriate to assess the effect of bronchodilation on exercise performance. These outcome measures will inform future clinical trials of the impact of bronchodilation on functional status (28).

CONCLUSIONS

Limb muscle dysfunction has implications for exercise intolerance and the exercise response to bronchodilation. It constitutes an important mechanism through which exercise training improves exercise tolerance in COPD.

CONFLICTS OF INTEREST: None.

REFERENCES

Obstructive sleep apnea syndrome across the life span:
Adult perspective
John A Fleetham
Respiratory Division, University of British Columbia, Vancouver, British Columbia
E-mail John.Fleetham@vch.ca

Sleep disordered breathing (SDB) is associated with important health and economic consequences. SDB consists of four distinct clinical syndromes, namely, obstructive sleep apnea-hypopnea syndrome (OSAHS), central sleep apnea-hypopnea syndrome (which includes Cheyne-Stokes breathing syndrome), sleep hypoventilation syndrome and complex sleep apnea-hypopnea. Each syndrome has diagnostic and severity criteria. OSAHS is a clinical syndrome with symptoms, associated features and a differential diagnosis, and is characterized by recurrent episodes of partial or complete upper airway obstruction during sleep (1). In adults, OSAHS and Cheyne-Stokes breathing syndrome are common, whereas central sleep apnea-hypopnea syndrome (other forms of central), sleep hypoventilation syndrome and complex sleep apnea-hypopnea are rare. OSAHS is present in 4% of adult men and 2% of adult women, and becomes more common after menopause (2).

Excessive daytime sleepiness is the hallmark symptom of OSAHS in adults. Other symptoms include nocturnal choking, recurrent nocturnal awakenings, unrefreshing sleep and impaired concentration. OSAHS can be an exacerbating factor for systemic hypertension, cardiac arrhythmias, depression and diabetes, which are frequently present in adult patients. The majority of adult patients with OSAHS have no specific upper airway abnormality, although macroglossia, retrognathia and upper airway neuromuscular disorders are present in some patients (Table 1). Upper body obesity results in fat deposition both in and around the airway, and is a major risk factor for OSAHS. Furthermore, OSAHS is present in 10% to 20% of the first-degree relatives of patients with OSAHS. Excessive daytime sleepiness results in a higher rate of motor vehicle crashes and work-related accidents. Patients with OSAHS and an apnea/hypopnea index of greater than 15 events/h are seven times more likely to have multiple motor vehicle crashes over a five-year period than individuals without OSAHS (3,4). These crash rates return to normal with effective treatment (5). The majority of the evidence implicating OSAHS as a cause of both cardiovascular and cerebrovascular disease is indirect, due to limited availability of long-term data. Fatal and nonfatal cardiovascular events are much more common in patients with severe OSAHS than in control subjects or in patients with OSAHS treated with continuous positive airway pressure (CPAP) (Figure 1) (6). Robust clinical trial data now show that OSAHS is independently associated with systemic hypertension, and that blood pressure falls when severe OSAHS is treated with CPAP (7). Patients with OSAHS have increased health care expenditures and before diagnosis, patients with SDB use health care services at approximately twice the rate of control subjects (8).

**TABLE 1**
Obstructive sleep apnea-hypopnea syndrome high-risk groups (adults)

<table>
<thead>
<tr>
<th>Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper body obesity</td>
</tr>
<tr>
<td>Craniofacial abnormality</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>Macroglossia</td>
</tr>
<tr>
<td>Acromegaly</td>
</tr>
<tr>
<td>Amyloidosis</td>
</tr>
<tr>
<td>Neurological disorders</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
</tr>
<tr>
<td>Muscular dystrophy</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>Spinal cord injury</td>
</tr>
<tr>
<td>Black race</td>
</tr>
</tbody>
</table>

**Familial**

- Familial
- Male
- Black race
- Diabetic
- Obstructive sleep apnea
- Hypertension
- Obstructive sleep apnea-hypopnea syndrome high-risk (OSAHS)
- Central sleep apnea-hypopnea syndrome (other forms of central)
- Sleep hypoventilation syndrome
- Complex sleep apnea-hypopnea

**Figure 1** Nonfatal cardiovascular (CVS) events in the control group, patients with severe obstructive sleep apnea-hypopnea (OSAHS) and OSAHS patients treated with continuous positive airway pressure (CPAP). Adapted from reference 6

Weight loss should be encouraged in all obese patients with OSAHS. CPAP at a fixed pressure is the primary treatment for patients with OSAHS, although an oral appliance is an appropriate therapy for patients with mild to moderate OSAHS with minimal daytime symptoms. Although uncommon, the presence of large tonsils in a patient with OSAHS should prompt referral to an otolaryngologist for consideration of tonsillectomy. Treatment of OSAHS is a cost-effective use of healthcare resources. CPAP treatment decreases health care expenditures during the first two years after diagnosis of OSAHS (9).

There are important differences in OSAHS between children and adults (Table 2). Excessive daytime sleepiness is common in adults, whereas in children it is less common and should raise the possibility of another sleep disorder such as narcolepsy. The majority of children with OSAHS have enlarged tonsils, whereas most adults have no specific upper airway abnormality. Diagnostic criteria also differ between adults and children. Neurocognitive consequences are predominant in children, whereas cardiovascular consequences are predominant in adults. Adult patients also face the additional risk of a motor vehicle crash. Adenotonsillectomy is the primary treatment for OSAHS in the majority of children, whereas CPAP is the primary treatment in adults.
TABLE 2
Comparison of the important differences between obstructive sleep apnea hypopnea in children and adults

<table>
<thead>
<tr>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less sleepy</td>
<td>Symptoms</td>
</tr>
<tr>
<td>Large tonsils</td>
<td>Signs</td>
</tr>
<tr>
<td>AHI &gt;1.5</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>Cardiac/metabolic</td>
<td>Consequences</td>
</tr>
<tr>
<td>Neurocognitive/behaviour</td>
<td>Treatment</td>
</tr>
</tbody>
</table>

Conflicts of interest: None.

REFERENCES
5. George CF. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 2001;56:508-12.

Obstructive sleep apnea across the life span: Pediatrics perspective
Valerie Gail Kirk MD FRCPAC
Alberta Children's Hospital, Calgary, Alberta
Email val.kirk@calgaryhealthregion.ca

In 1889, Dr William Hill published an account of “the stupid adenoid physiognomy” in an article in the British Medical Journal entitled “On some causes of backwardness and stupidity in children” (1). The paper clearly described children suffering from what we now recognize as obstructive sleep apnea (OSA), with a focus on the behavioural and learning effects in the developing child. The present paper provides a brief review and update on the current state of knowledge regarding the presentation, effects and treatment options for children with OSA.

Definition
OSA in children is “a disorder of breathing during sleep characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction that disrupts normal ventilation during sleep and normal sleep patterns” (2). Snoring alone is present in 7% to 9% of otherwise healthy children, and OSA in 2% to 3% (3,4). Due to the decreased collapsibility of upper airway structures in children, airway obstruction during sleep is uncommon in this population (5), and cut-off values indicating disease are much lower. There is also a higher incidence of partial airway obstruction with coexistent hypercapnea in children younger than 18 years of age (6,7) (Table 1).

CRITERIA
Given that the clinical significance of abnormal polysomnographic findings is not yet well defined in pediatrics, recommendations are based on a combination of clinical findings, history, and polysomnography. The most common clinical presentations in children are different than those in adults, although there is a rising frequency of obesity-related sleep disordered breathing in North American children (4) (Table 2).

Table 1: Normative data for polysomnography in children

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apnea-hypopnea index</td>
<td>&lt;1.5/h</td>
</tr>
<tr>
<td>Minimum oxygen saturation</td>
<td>≥90%</td>
</tr>
<tr>
<td>Maximum carbon dioxide</td>
<td>≤53 mm Hg</td>
</tr>
<tr>
<td>Sleep efficiency</td>
<td>&gt;85%</td>
</tr>
<tr>
<td>Arousal index</td>
<td>&lt;11/h</td>
</tr>
</tbody>
</table>

Table 2: Common presenting signs and symptoms of obstructive sleep apnea in children

<table>
<thead>
<tr>
<th>Daytime</th>
<th>Nighttime</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperactivity</td>
<td>Snoring, noisy breathing</td>
</tr>
<tr>
<td>Learning problems</td>
<td>Difficulty breathing</td>
</tr>
<tr>
<td>Difficulty concentrating</td>
<td>Witnessed apnea</td>
</tr>
<tr>
<td>Mood/behaviour control</td>
<td>*Excessive daytime sleepiness is less common in children with obstructive sleep apnea and should increase suspicion for narcolepsy</td>
</tr>
<tr>
<td>Mouth-breathing</td>
<td></td>
</tr>
<tr>
<td>Poor growth</td>
<td></td>
</tr>
<tr>
<td>Excessive daytime sleepiness</td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td></td>
</tr>
<tr>
<td>Nighttime</td>
<td></td>
</tr>
<tr>
<td>Snoring</td>
<td></td>
</tr>
<tr>
<td>Difficulty breathing</td>
<td></td>
</tr>
<tr>
<td>Witnessed apnea</td>
<td></td>
</tr>
</tbody>
</table>

Risk groups
Although OSA most often occurs in otherwise healthy children, those with the following abnormalities are at higher risk and may warrant screening: adenotonsillar hypertrophy, craniofacial abnormalities (eg, Down syndrome), neurological disorders (eg, cerebral palsy) and obesity (8,9).

Effects
Untreated OSA has well-documented effects on learning, behaviour, school performance and mood (10-12). Studies of the metabolic and cardiovascular effects of OSA in this age group have had mixed results. Affected children can develop
ventricular dysfunction and/or hypertension, but it is not yet clear what role obesity plays in this relationship. Recent reports of increased serum levels of interleukin-6, C-reactive protein and endothelial markers as well as an increased density of leukotriene receptors in the tonsil and adenoid tissue in children with OSA suggest a role for inflammation in the pathogenesis (13-15).

**TREATMENT**

The majority of children with OSA will have a successful outcome with routine adenotonsillectomy (80% to 95% cure rate) (16). Among those with complicating disorders such as Down syndrome and/or obesity, approximately 50% require additional treatment with continuous positive airway pressure (16,17). More recently, pharmacological therapy with a combination of nasal steroid spray and leukotriene inhibitors has been shown to improve symptoms and polysomnography findings in children with mild residual OSA postadenotonsillectomy (18,19). Lastly, treatment of selected children who have both OSA and dental malocclusion with a rapid-technique maxillary spacing device has shown promising results (20).

**SUMMARY**

OSA in children is a common disorder that presents most frequently with learning and/or behavior problems. Polysomnographic diagnostic criteria are well established but there remains a paucity of data regarding which markers correlate most closely with clinically significant outcomes. The mainstay of treatment for otherwise typical children continues to be adenotonsillectomy, but continuous positive airway pressure can be used with success when needed. Newer pharmacological and orthodontic treatment techniques are currently being developed.

CONFLICTS OF INTEREST: None.

REFERENCES


The future of Canadian respiratory clinical research

Shawn D Aaron MD

Division of Respiratory Medicine, The Ottawa Hospital, Ottawa, Ontario

E-mail saaron@ohri.ca

The objectives of the present article are to identify future challenges in Canadian clinical respiratory research; and new opportunities in Canadian clinical respiratory research.

Clinical research is usually defined as patient-oriented research. It is: “Research that requires interaction between a clinician-investigator and a patient.” Clinical researchers study diseases in humans both at a population level and at an individual patient-level. They study disease causation, treatment, and delivery of health care services. High-quality clinical research is essential to understanding disease in humans and to improving health care. Without clinical research, we cannot possibly understand risk factors for development of disease, whether new therapies may be beneficial, or which current therapies might be harmful.

Canadian respiratory research has performed strongly in the recent past. From 1993 to 2003, Canadians collectively published 2612 respiratory research articles in journals with an average impact factor of three. Our respiratory research output during these eight years, adjusted per population and gross domestic product, is ranked number one in the world (1).
However there are storm clouds on the research horizon. Funding for clinical research in Canada is very constrained; at the Canadian Institutes of Health Research (CIHR), there are 52 research grant review committees but only seven of these are devoted to funding clinical research. Currently, there are three Cardiovascular Disease committees at the CIHR, but only one Respiratory Systems Committee. Of 35 grants submitted to the Respiratory Systems Committee in September 2007, only 10 could be funded, and of these 10 grants, only one was for a clinical research project.

Lung cancer killed more than 18,000 Canadians in 2005, more than twice the number of the next most deadly cancer, colorectal cancer, which killed 8000 Canadians. However, in that same year, lung cancer received less than $8 million in total research funding in Canada, compared with $38 million for breast cancer, $20 million for leukemia and $12 million for colorectal cancer. Similarly, total 2006 funding for AIDS research was more than double the amount of funding awarded to all pulmonary diseases combined. Clearly, research pertaining to lung diseases is chronically underfunded, and this is a threat to the future of respiratory clinical research in Canada.

Other challenges for clinical research in Canada include a complex regulatory environment that includes needs for clinical trial agreements, Health Canada approval of clinical trials, ethics submissions and data safety monitoring. All of these requirements are necessary to ensure safe clinical research practices, but add complexity and challenges to clinical research projects. The hurdles involved in setting up a clinical research project are thus considerable. This may discourage young physician investigators or other young health professionals from pursuing a career in clinical research. Finally, competition is intense, and to be published in top-rated journals, clinical research studies now have to be large, often enrolling thousands of patients. This requires clinical researchers to collaborate with one another to enroll an adequate number of patients.

Recently, to meet the above listed challenges, respiratory clinical researchers in Canada have come together to form The Canadian Respiratory Clinical Research Consortium (CRCRC). The goals of the CRCRC are to foster national collaborative multicentre research in pulmonary medicine, to attract additional funding for Canadian collaborative research, and to foster additional collaborative Canadian studies such as randomized clinical trials, cohort studies, systematic reviews, epidemiological studies and evaluations of diagnostic tests. The CRCRC has thus far been very successful, and has held three annual national meetings and published several large collaborative Canadian clinical research studies (www.crcrc.ca).

What can we do to move the future of Canadian clinical research forward? We can work together as a group to establish strong, successful collaborative clinical research networks, and this is being done through the CRCRC. We can lobby governments and the CIHR to create more funding opportunities for respiratory research and for clinical research, so that funding becomes commensurate with the burden of respiratory diseases within Canada. Nothing breeds success like success. If we continue to be productive as respiratory researchers, and if we work together as a group, then we will be recognized nationally and internationally, and this will eventually breed more opportunity and more funding and more excellent research.

**CONFLICTS OF INTEREST:** None.

**REFERENCES**


**Canadian adult and pediatric 2008 asthma update**

Andrew McIvor MD MSc FRCP
McMaster University, St Joseph’s Healthcare, Firestone Institute for Respiratory Health, Hamilton, Ontario
E-mail amcivor@stjoseham.on.ca

The 2008 asthma update comprises a series of cases with ‘key points’ for asthma management. This will be accompanied by the simultaneous distribution of a number of related knowledge-translation tools. For the first time, the guidelines and collateral materials have been designed with the overarching goal of transforming evidence-based knowledge into clinical practice. By focusing on knowledge translation – as well as on the need for family doctors, certified asthma educators, pharmacists, and allied health care professionals to apply a chronic disease management model to asthma – the Asthma Committee of the Canadian Thoracic Society (CTS) believes that it can lead the way to improving asthma control, reducing exacerbations and mortality, and improving asthma report cards in future patient surveys.

The first asthma guidelines were produced by the CTS’s multidisciplinary Asthma Committee nearly two decades ago (1). Initially created via a process that included a consensus meeting, subsequent revisions and updates of the guidelines have involved extensive critical appraisal of emerging medical literature, thereby ensuring the creation of relevant, evidence-based reports (2,3).

However, in spite of the creation and dissemination of the sets of guidelines, various concomitant supportive initiatives, a number of comprehensive patient and physician surveys, and follow-up reports, poor asthma control persists in Canada. The most recent study assessing asthma control in Canada, the Canadian Asthma and Allergy Foundation of Canada (CAAfC) Personal Practice Assessment Programme, included more than 350 Canadian primary care physicians (4). It revealed that 59% of the more than 10,000 patients under a physicians’ treatment had uncontrolled asthma. It also clearly identified that if a patient is uncontrolled by one or more of the subjective criteria of asthma control (ie, no need to perform objective tests of lung function such as spirometry or peak flow), the patient is nearly six times as likely to have a subsequent unscheduled health care visit, 3.5 times more likely to have an emergency visit and twice as likely to be admitted to hospital.

It is somewhat disheartening that despite the excellent and constantly evolving therapeutic armamentarium, clinicians in Canada are not, for some reason, integrating guideline based recommendations into clinical care. They are not routinely performing office assessment of control, nor are they changing the way they manage their patients with asthma.

The CTS Asthma Committee therefore re-examined the way in which it had been producing and disseminating guidelines. The group came to the conclusion that it should shift more of its effort to knowledge translation rather than focusing almost exclusively on guideline production (5). The next set of
Chronic obstructive pulmonary disease: The importance of early diagnosis

Denis E O’Donnell MD
Division of Respiratory & Critical Care Medicine, Queens University, Kingston, Ontario
E-mail odonell@queensu.ca

Chronic obstructive pulmonary disease (COPD) is a major public health problem in Canada. It is currently the fourth leading cause of death and is destined to be the third by 2020 (1). Death rates and hospitalizations continue to escalate, particularly in older women (1,2). A recent study in Vancouver, British Columbia, undertaken as part of a global survey, determined prevalence rates of 7.3% and 9.3% in women and men, respectively (3). The Canadian Thoracic Society COPD management recommendations highlighted the central importance of early diagnosis (4).

Most patients with COPD escape diagnosis until their respiratory reserve is critically diminished. The respiratory impairment reflects a combination of the natural decline of lung function with aging and a superimposed airway and lung inflammation from tobacco smoke. Symptomatic smokers, with a high pretest probability of having the disease, should undergo simple spirometry (Table 1). A post-bronchodilator forced expiratory volume in 1 s (FVC) forced vital capacity ratio of less than 0.7 confirms the presence of airflow obstruction that is not fully reversible. Mild COPD is an FEV1 greater than 80% predicted. A recent study has provided reassurance that fixed ratio criteria have sufficient diagnostic sensitivity for targeted screening of the disease (5).

Recent studies by Hogg et al (6) have confirmed that patients with mild airflow obstruction have evidence of airway inflammation. Patients with preserved FEV1 may have extensive small airway dysfunction as measured by closing volume and tests of abnormal distribution of ventilation (7-9). Ventilation-perfusion inequalities contribute to a higher than normal ventilatory requirement during physical exertion. Some patients with mild airflow obstruction seek medical attention because of reduced health status, chronic activity-related dyspnea and reduced activity levels (10). During cardiopulmonary exercise testing, they exhibit expiratory flow limitation and dynamic pulmonary hyperinflation which contributes to exertional dyspnea and exercise intolerance (11).

The identification of mild COPD should lead to activation of a strategic management plan that includes smoking cessation, which favourably impacts the natural history of the disease (12). Other interventions include annual influenza vaccination (13,14), active encouragement of regular physical activity and annual follow-up that includes spirometry. No evidence-based guidelines exist with respect to pharmacotherapy in mild COPD. The Canadian Thoracic Society panel recommended a trial of short-acting bronchodilator therapy in spirometry-confirmed symptomatic patients (4). If activity-related dyspnea persists, a long-acting bronchodilator could be added. Inhaled corticosteroids are not beneficial in early COPD (15,16).

CONFLICTS OF INTEREST: None.

REFERENCES

TABLE 1
Who should be targeted for spirometry?

<table>
<thead>
<tr>
<th>Smokers or ex-smokers older than 40 years of age if they answer ‘yes’ to any of the following questions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Do you cough regularly?</td>
</tr>
<tr>
<td>2. Do you cough up phlegm regularly?</td>
</tr>
<tr>
<td>3. Do even simple chores make you short of breath?</td>
</tr>
<tr>
<td>4. Do you wheeze when you exert yourself or at night?</td>
</tr>
<tr>
<td>5. Do you get frequent colds that persist longer than those of other people you know?</td>
</tr>
</tbody>
</table>

Registration can be found at wwwMDcme.ca, and I encourage you all to access this.

CONFLICTS OF INTEREST: Dr McIvor has received honoraria for providing CME and attending advisory boards from AstraZeneca, Boehringer-Ingelheim, Graceway, GlaxoSmithKline, Merck, Novartis and Pfizer.


